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Abstract 
 The increased frequency of antibiotic resistant bacterial isolates is of great 
concern for public health. It is currently estimated that infections caused by multidrug 
resistant pathogens will surpass cancer as a leading cause of death by 2050 (1). Of 
particular concern are gram-negative bacteria, due to their robust intrinsic resistance 
provided by a low permeability outer membrane barrier in combination with active 
efflux. Active efflux is mainly mediated by Resistance-Nodulation cell Division (RND) 
transporters, which associate as tripartite complexes that facilitate the export of 
substrates across the outer membrane. These two mechanisms of resistance work in 
synergy to efficiently limit intracellular accumulation of antibiotics. This directly results 
in very low hit rates during antimicrobial screenings and presents unique challenges in 
the development of antibiotics. 
 In addition to providing resistance, RND transporters are also involved in the 
physiology of bacteria. Pseudomonas aeruginosa possesses twelve RND transporters of 
which three are indicated to be involved in its quorum sensing networks. 
Overexpressing or deleting the genes of these transporters has a great physiological 
impact and can result in a loss of virulence or extended lag phases during growth. In 
many cases, the endogenous substrates of these transporters are not known and their 
impact on the physiology of the cell is not well understood. 
 This dissertation focuses on the interplay between the low permeability outer 
membrane and active efflux in drug resistance and their contribution to physiology of P. 
aeruginosa. Current methods to investigate the contributions of the outer membrane 
barrier in drug resistance, like the use of polymyxins to permeabilize the outer 
xiv 
membrane, have many disadvantages. Here, we developed a novel approach to separate 
the contributions of efflux and the outer membrane in antimicrobial susceptibility by 
introducing a genetically modified pore that non-selectively increases the permeability 
of the outer membrane. In combination with the removal of efflux transporters, this 
hyperporination approach highlights the synergy of the outer membrane and efflux, and 
has potential implications for the development of new antibiotics. It could provide the 
means to discover new rules in drug design that predict the uptake of a compound into 
the gram-negative cell according to its structural features. 
 Furthermore, this dissertation will characterize the contributions of the RND 
transporter MexGHI-OpmD from P. aeruginosa in the physiology and antimicrobial 
resistance of the bacterium. Our results suggest that the transporter is involved in 
establishing the steady-state concentrations of the important virulence factor pyocyanin. 
In addition, we showed that the unusual fourth component MexG physically interacts 
with the transporter and that its presence results in inhibition of the efflux activity 
towards certain substrates. Our results suggest that the activity of RND transporters are 
masked by the presence of the outer membrane and that hyperporination highlights the 
actual transport efficiencies of these pumps. RND transporters heavily rely on the outer 







 Bacterial infections are as old as mankind itself. From the bubonic plaque, to 
leprosy, to malaria, and tuberculosis bad bugs have been the cause of many epidemics 
and millions of lives lost. Alexander Fleming discovered penicillin in the mid-1900s 
and with it the ultimate weapon to fight bacteria. As antibiotic discovery accelerated it 
seemed like only a matter of time until these diseases would disappear forever. With the 
onset of antibiotic resistance, however the idea of eradicating these pathogens has 
become less likely. Decades of misuse of antibiotics in farming and overprescribing by 
doctors constantly put selective pressure on bacteria to develop sophisticated resistance 
mechanisms. Today, the threat of multidrug resistant (MDR) superbugs is more real 
than ever. A recent discovery in a US hospital of a Escherichia coli strain resistant to 
carbapenems as well as the last resort antibiotic colistin shows how close we are to 
bacteria that are completely resistant to all conventionally used antimicrobials (2). In 
the US alone, current estimates range from a $21 to $34 million in health care costs, and 
even a decrease in the GDP by 0.4% to 1.6% due to the increased recovery time of 
patients (3). A report by the UK government estimated that by 2050 as many as 10 
million people will die from diseases caused by multidrug resistant bacteria, passing 
even cancer with a projected 8.1 million deaths (1).  To make matters worse, current 
antibiotic discovery has slowed down dramatically with the last class of antibiotics, the 
cyclic lipopeptides, discovered in the late 1980s (3). It has become clear that we will 
lose the race against fast evolving superbugs without any significant innovations in the 
field. 
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 There are several mechanisms by which cells can become drug resistant. 
Bacteria can modify the target of a particular antimicrobial through a single point 
mutation and this way reduce binding of the drug to its target (4). In addition to 
mutations of the target, bacteria also modify them by, for example, methylation which 
can prevent binding of the drug (4). Another clinically relevant mechanism of drug 
resistance is modification of the antibiotic itself (4). Bacteria express enzymes that can 
hydrolyze or acetylate antibiotics rendering them ineffective. Genes expressing these 
enzymes are often rapidly spread to entire populations through horizontal gene transfer 
and are a major area of research. However, arguably the most effective way for cells to 
become resistant against multiple classes of antibiotics is by decreasing the permeability 
of the cell envelope by modifying the cell membrane in combination with active drug 
efflux.  
 This is especially true for gram-negative bacteria and their highly impermeable 
outer membranes (5). In contrast to gram-positive bacteria, the cell envelope of gram-
negatives is made up of two distinct membranes. The inner membrane and the inner 
leaflet of the outer membrane are mainly made up of phospholipids that provide good 
protection for hydrophilic molecules to enter the cell. The outer leaflet of the outer 
membrane consists of lipopolysaccharides (LPS), which due to the presence of large 
polar sugar groups is highly hydrophilic. LPS reduces the permeation of hydrophobic 
molecules, which encompasses a large part of antibiotics. This combination makes it 
incredibly difficult for drugs to reach their target and carry out their activity.  
 In addition to this low permeability of the outer membrane, gram-negative 
bacteria also have several efflux transporters. The class of transporters that is most 
3 
commonly associated with antibiotic resistance in bacteria are RND type transporters. 
They are tripartite protein complexes that span the entire cell envelope, allowing them 
to export substrates across the outer membrane and out of the cell. This feature leads to 
a synergistic effect with the low permeability barrier of the outer membrane and makes 
infections of gram-negative bacteria incredibly hard to treat.  
 It is no surprise that the three bacterial species that make up the priority one 
group for the development of new antibiotics of the World Health Organization are 
highly resistant gram-negative bacteria (6). The most critical species are Acinetobacter 
baumannii, Pseudomonas aeruginosa, and some carbapenem resistant 
Enterobacteriaceae (6). Drug development for gram-negatives specifically also 
provides extra challenges. The low permeability of these bacteria poses a big challenge 
in drug screening, decreasing the hit rate of compounds by up to a staggering 1,000-fold 
(7). Taken together, multidrug resistant gram-negative pathogens represent a 
tremendous challenge for the scientific community, and new ways to treat such 
infections are desperately needed. 
This dissertation will focus on understanding the interplay of outer membrane 
permeability and active efflux of the gram-negative, opportunistic pathogen P. 
aeruginosa, and on characterization of the P. aeruginosa RND transporter MexGHI-
OpmD and its impact on drug resistance and physiology. P. aeruginosa most infamous 
for nosocomial diseases and lung infections in cystic fibrosis patients (8). Infections can 
be acute or chronic and are difficult to treat due to the high intrinsic resistance of the 
bacterium. Acute infections are caused by planktonic cells, which typically invoke a 
severe immune response in the patient (9). The most effective class of antibiotics used 
4 
against these infections are fluoroquinolones (10, 11). In cases of multidrug resistant 
strains, patients undergo either a continuous infusion of meropenem, treatment with 
colistin, or polymixin B (12), all of which are considered last resort antibiotics. Chronic 
infections are caused by colonization of P. aeruginosa grown as biofilms, which are 
made up of exopolysaccharides, extracellular DNA, and proteins (9, 13). This structure 
provides an additional layer of resistance for the pathogen due to the high rate of 
persister cells and the slow mode of growth (14). The increased frequency of multidrug 
resistant isolates of P. aeruginosa is of great concern and necessitates the discovery of 
new approaches to combat the pathogen (6, 15-17).  
 
I.1: Structure and properties of the bacterial outer membrane 
Intrinsic resistance in gram-negative pathogens is mainly mediated by the 
structure and composition of the outer membrane and active efflux. The bacterial outer 
membrane is quite different from the inner membrane (Fig. I.1). The inner leaflet of the 
outer membrane, like the bacterial inner membrane, consists mainly of phospholipids. 
What makes the outer membrane distinctly different is the outer leaflet, which is made 
up of lipopolysaccharides (LPS). LPS is well known for its toxic effects, as it is 
sometimes referred to as endotoxin. It can invoke severe immune responses in 
mammalian hosts and lead to septic shock (18). However, it also plays a big role in the 
structure of the cell envelop of gram-negative bacteria. The asymmetric bilayer of LPS 
and phospholipids makes gram-negative bacteria uniquely impermeable (5). The 
structure of LPS has been studied extensively (19-28). LPS consists of lipid A, an inner 
and an outer core, as well as a large stretch of polysaccharides referred to as O-antigen.  
5 
Lipid A typically consists of two phosphorylated glucosamine moieties that are 
N- and O-acylated (26). The exact structure of lipid A can vary between bacterial 
species. In P. aeruginosa, the major forms are hexa- and penta-acylated lipid A (19, 
21). Variations in the acylation occurs as a result of different growth conditions, such as 
the amount of available Mg2+ in the environment (19). The acyl chains are either 10 or 
12 carbons in length and form the hydrophobic portion of the molecule (26). The 
acylation pattern and length of the acyl tails differ in other species. E. coli, for example, 
utilizes 12 to 14 carbon acyl chains and is typically hexa-acylated (25). 
The inner core of LPS is generally comprised of two ⍺-3-deoxy-D-manno-oct-2-
ulosonic acid (Kdo) and two L-glycero-D-manno-heptose (Hep) residues covalently 
linked to the glucosamine residues of lipid A (26). The second Hep residue of the inner 
core of P. aeruginosa has a carbamoyl group attached at the O-7 position, which 
appears to be unique to pseudomonads (24). In addition, the Hep residues are 
extensively phosphorylated by mono-, di-, and even triphosphate groups, which have 
been implicated in intrinsic resistance of P. aeruginosa (27, 28). The outer core consists 
mainly of D-galactosamine, D-glucose, and L-rhamnose residues with a characteristic 
L-alanyl group acylation at the D-galactosamine for P. aeruginosa (26).  
The O-antigen is a relatively large structure of different amino saccharides and 
can vary significantly between different isolates of P. aeruginosa. There are currently 
20 accepted serotypes of P. aeruginosa strains based on variability of the O-antigen (22, 
23). Notably, P. aeruginosa isolates found in cystic fibrosis lungs largely lack the O-




Figure I.1 - The gram-negative cell envelope.  
Illustration of the cell envelope of gram-negative bacteria. Transmembrane structures in 








 Taken together, LPS is a large and mostly polar structure that provides 
significant protection from hydrophobic molecules, which are thought to enter the cell 
through passive diffusion across the cell envelope. The outer membrane, with its 
asymmetric arrangement of LPS on the outer leaflet and phospholipids on the inner 
leaflet, forms a formidable barrier for a wide range of compounds and is one of the 
main reasons why gram-negative bacteria possess such high levels of intrinsic 
resistance. 
 
I.2 Outer membrane porins of gram-negative bacteria 
Despite this low permeability of the outer membrane, gram-negative cells are 
still able to take up nutrients for their metabolism. This is mainly achieved through 
passive diffusion through outer membrane porins (30). These porins can be specific, 
like the maltoporin LamB from E. coli, or general porins that have no substrate binding 
site (31). Specific porins usually have a binding site for their respective substrate 
whereas general porins do not (30). The most well-known general porins are OmpF and 
OmpC from E. coli. Their exclusion size largely dictates the permeability of the cell 
envelope for hydrophilic molecules and for OmpF is estimated to be about 600 Da (5, 
31).  In contrast to E. coli, P. aeruginosa largely lacks general porins. It expresses so-
called “slow porins” that are non-specific but with much smaller exclusion limits (5, 
30). The main slow porin in P. aeruginosa is OprF with an estimated exclusion size of 
about 200 Da (5, 30). The differences in outer membrane porins has a dramatic effect 
on permeability. It is estimated that the relative permeability of the cell envelope of P. 
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aeruginosa is only 1-8% when compared to E. coli (32). This underlines the stark 
differences between these bacteria and highlights the difficulties in designing 
antipseudomonal drugs. 
 
I.3 MDR transporters in bacteria 
 In bacteria, multidrug resistance transporters generally belong to one of five 
superfamilies of proteins: the Major Facilitator Superfamily (MFS), the Multidrug 
Toxic Compound Extrusion (MATE) superfamily, the Small Multidrug Resistance 
(SMR) superfamily, the ATP-Binding Cassette (ABC) superfamily, and the Resistance 
Nodulation cell Division (RND) superfamily (33). These transporters differ in their 
structure, energy dependence, composition, and substrate specificities (34-38). They are 
all located in the inner membrane and generally follow the same mechanistic principles 
of substrate binding, reorienting of the substrate towards the periplasm, and releasing 
the substrate based on reduced affinity to the transporter after the conformational 
change. The families are broken down into primary and secondary transporters. ABC 
transporters are the only primary transporters and utilize ATP to facilitate efflux (34). 
MFS, SMR, MATE, and RND transporters all use a chemical gradient, mostly protons 
and sodium ions, to drive their conformational changes (33). In gram-negative bacteria, 
MDR transporters can associate with so called membrane fusion proteins (MFP) and 
outer membrane factors (OMF) to form a complex that spans the entire cell envelope.  
 RND transporters are the most commonly associated with clinical drug 
resistance in gram-negative bacteria. This is mostly due to their very broad substrate 
specificity and because they are almost always found in complexes with MFPs and 
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OMFs, allowing them to translocate substrates across the outer membrane into the 
extracellular space (33, 38). Transport across the outer membrane coupled with its low 
permeability leads to powerful and synergistic resistance mechanism.  
 The chromosome of P. aeruginosa specifically encodes for at least twelve RND 
transporters, many of which are constitutively expressed (39). The most clinically 
relevant transporters are MexAB-OprM(40), MexCD-OprJ (41), MexEF-OprN (42, 43), 
and MexXY (43). They generally have a very broad substrate specificity and are 
frequently found to be overexpressed in clinical isolates (43). MDR transporters 
contribute tremendously to the resistance of P. aeruginosa and, consequently, 
considerable effort is dedicated to finding inhibitors of efflux pumps (44). Some efflux 
pump inhibitors (EPIs) like PAβN have already been described and show promising 
results (45). However, EPIs are not available in clinical settings yet and more work is 










Figure I.2 - Types of bacterial MDR transporters. 
Representatives of the five MDR superfamilies from gram-negative bacteria. Although 
only AcrB is shown in complex with MFP and OMF, MFS and ABC transporters can 
also form tripartite complexes (46, 47). MFS transporters are thought to act as 
monomers, however are sometimes found as dimers (48). Areas shaded in blue indicate 
the inner and outer membrane, and substrates are indicated as orange hexagons. 
Structures modified from PDB files 4HUK (NorM, Lu et al. (49)), 2GFP (EmrD, Yin, et 
al. (50)), 5O66 (AcrAB-TolC, Wang, et al. (51)), 5NIK (MacB, Fitzpatrick, et al. (52)), 
and 2I68 (EmrE, Fleishman, et al. (53)). 
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I.4 Mechanism of RND transporters 
RND transporters work in concert with membrane fusion proteins (MFPs) and 
outer membrane channels (OMFs) to expel their substrates out of the cell. This tripartite 
complex is critical to provide efflux across the bacterial outer membrane. Every part of 
the complex is essential, and a deletion of one component completely abolishes the 
activity of the transporter (54, 55). Interactions between the transporter, the MFP, and 
the OMF are strong, so that the components are frequently co-purified together (56, 57). 
The fully assembled complex spans the entire cell envelope, allowing it to expel 
substrates from the inner membrane, or the interphase between the periplasm and the 
inner membrane, across the outer membrane (58). This is cause for significant synergy 
between the efflux pump and the low permeability outer membrane. RND transporters 
are secondary transporters and use the proton motive force to supply the energy needed 
to translocate substrates (38). The most well-known members of this family are AcrAB-
TolC from E. coli and MexAB-OprM from P. aeruginosa. They share a high sequence 
homology and both provide resistance to a broad spectrum of antibiotics (59).  
The RND component of the complex is located in the inner membrane. It 
associates as a trimer, with each monomer containing 12 transmembrane ɑ-helices (TM) 
and two large periplasmic loops (38). The RND protein is usually divided into the 
transmembrane domain, the porter domain, and the docking domain (Fig. I.3) (60). The 
transmembrane domain anchors the transporter into the inner membrane and contains 
the residues needed for the proton relay network. There are typically two highly 
conserved aspartic acid residues and one lysine residue on TM4 and TM10, which 
facilitate the movement of protons from the periplasm to the cytoplasm (38). This 
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results in a conformational change in the transmembrane domain, which ultimately 
facilitates the transport reaction. The porter domain is subdivided into PN1, PN2, PC1, 
and PC2 domains, each of which contains four to five β-strands forming an antiparallel 
β-sheet and two ⍺-helices (60). It contains the proximal and the distal binding pockets 
that are separated by a switch-loop (61). Both pockets are typically rich in 
phenylalanines and other hydrophobic residues, making them ideal to non-specifically 
bind many different hydrophobic antibiotics and other compounds (62). The docking 
domain forms a funnel like structure which guides the substrates towards the OMF for 



















Figure I.3 - Structure of RND transporters. 
 
Side view of the RND transporter AcrB from E. coli. Each monomer is shown in a 
different color. Dotted lines separate the three different domains. Inner membrane is 
indicated by the blue shaded area. Residues of the substrate binding pocket are shown in 





RND transporters facilitate the transport reaction through an asymmetric 
functional rotating mechanism (60). Each protomer is generally present in one of three 
conformations and will switch between the “loose” or “access” form, the “tight” or 
“binding” conformation, or the “open” or “extrusion” form (38). Each conformer differs 
slightly in the structure of the binding pockets and the protonation state of the proton 
relay network in the transmembrane domain. The changes in the binding pockets 
effectively guide the substrate from the proximal pocket to the distal pocket and 
ultimately out of the transporter through the docking domain (62). Substrates are 
thought to enter the binding pockets close to or at the interphase between the periplasm 
and the inner membrane via an access tunnel and are moved through the transporter by 
a peristaltic pump like mechanism, which is energized by the movement of protons in 
the transmembrane domain (60). 
 
I.5 Membrane fusion proteins connect the RND transporter to the OMF 
MFPs, also sometimes called periplasmic adaptor proteins, form a link between 
the RND transporter and the OMF. They consist of four distinct domains and like RND 
transporters are a peptide strand folded onto itself, which is likely the result of a gene 
duplication event. MFPs consist of a membrane proximal domain, a β-barrel domain, a 
lipoyl domain, and a ɑ-hairpin domain (Fig. I.4) (64). Additionally, some MFPs, like 
MexH of MexGHI-OpmD, possess a lipid modification at the membrane proximal 
domain embedding the peptide into the inner membrane (65). The membrane proximal 
domain and the β-barrel domain are thought to interact with the RND transporter, 
whereas the ɑ-hairpin domain binds to the OMF (64). Between domains is a stretch of 
15 
unstructured amino acids, making the overall structure of MFPs highly flexible (66). It 
is thought that they transfer the energy from conformational changes in the RND 
transporter during transport to the OMF (67). This ultimately causes the OMF to open, 
allowing for substrates to leave the cell (68). There was much debate on whether MFPs 
associate as timers or hexamers. To date, the most widely accepted quaternary structure 
is a trimer of dimers or a hexamer (69-71). In the oligomeric state, MFPs are thought to 
form a funnel like structure that surrounds the docking domain of RND transporters and 






Figure I.4 - Four domains of membrane fusion proteins (MFPs). 
Crystal structure of the membrane fusion protein AcrA from E. coli. Each domain is 
shown in a different color. Unstructured stretches of amino acids between the four 
domains result in a highly flexible structure. Structure modified from PDB 5O66 





I.6 Outer membrane factors guide substrates out of the cell 
OMFs are channel proteins that are inserted into the outer membrane of gram-
negative bacteria. They are typically promiscuous and can interact with different types 
of transporters. E. coli’s main OMF TolC, for example, interacts with at least nine 
transporters, making a tolC mutant highly susceptible to many different antibiotics (72). 
OMFs are not unique to RND transporters. They can also be found in transporters from 
the major facilitator and ATP binding cassette families, usually accompanied by MFPs 
to facilitate the interaction (72). OMFs consist of three domains and associate as a 
homotrimer (Fig. I.5) (70). The β-barrel domain is embedded into the outer membrane 
and forms the pore that allows substrates to leave the cell (73). This directly follows the 
ɑ-barrel domain, which stretches far into the periplasm (70). Each protomer forms four 
large ɑ-helices that are interrupted briefly by short β-strands that make up the equatorial 
domain in the center of the ɑ-barrel domain (70). The end of the ɑ-barrel domain forms 
a type of iris that is closed when the OMF is not engaged by a transporter (73). It is 
thought that interaction of the docking domain of RND transporter engages and opens 
the channel, allowing for substrates to be expelled (55, 73). However, other studies 
suggest that the RND transporter and the OMF do not directly contact each other (74). 
Furthermore, ABC and MFS transporter lack large periplasmic domains that could 







Figure I.5 - Structural features of outer membrane factors. 
Outer membrane factors associate as trimers and consist of three different domains. 
Each monomer is shown in a different color. TolC is shown in the open conformation. 
Outer membrane is indicated by the blue shaded area. Structure modified from PDB 






I.7 Quorum sensing and the role of efflux pumps in virulence of P. aeruginosa 
 In P. aeruginosa, genes responsible for virulence and biofilm formation are 
tightly regulated by a complex network of transcription factors and transcriptional 
activators that are activated once a certain cell density is reached (Fig. I.6) (76). This 
type of cell-to-cell communication, which is commonly referred to as quorum sensing, 
is critical to orchestrate gene expression across a cell population and to initiate the 
production of virulence factors like pyocyanin, rhamnolipids, and elastase (13, 76). 
Quorum sensing signaling pathways are hierarchically ordered and start with the las and 
rhl systems, which are homologous to the LuxI/LuxR signaling mechanism in Vibrio 
fischeri (Fig. I.6) (76, 77). The family of LuxI type proteins are acyl homoserine lactone 
(AHL) synthases, which synthesize AHLs by catalyzing the acylation of S-
adenosylmethionine via an acyl carrier protein (76, 77). The synthesized AHLs are 
typically excreted into the extracellular space and serve as signaling molecules (76). 
Once the extracellular concentration is high enough, they will bind to their respective 
cytoplasmic LuxR type receptors which, in turn, upregulate expression of certain genes 
(78). In P. aeruginosa, the las and rhl system synthesize the signaling molecules N-(3-
oxododecanoyl)-L-homoserine lactone (3OC12-HSL) and N-butanoyl-L-homoserine 
lactone (C4-HSL) respectively (76). The other major signaling pathway of P. 
aeruginosa is through the Pseudomonas Quinolone Signal (PQS). PQS is synthesized 
by pqsABCDH and its corresponding receptor is PqsR (77). The las system upregulates 
PQS synthesis, whereas the rhl pathway downregulates it (Fig. I.6) (77). This highlights 
the complexity and the way these pathways are interconnected. Activation of PqsR 




Figure I.6 - Quorum sensing network in P. aeruginosa. 
The major quorum sensing pathways in P. aeruginosa and their corresponding signaling 









 Quorum signaling molecules are of great importance for virulence and biofilm 
formation, and cells require careful regulation of these molecules. Some RND 
transporters were found to be involved in excretion of these molecules, highlighting the 
importance of these efflux pumps outside of the removal of toxic compounds. So far, 
MexAB-OprM (79, 80), MexEF-OprN (81, 82), and MexGHI-OpmD (83, 84) are 
indicated to be involved in maintaining quorum sensing signal homeostasis. 
Overexpression of MexAB-OprM, for example, was found to result in a dramatic 
decrease of the production of the important virulence factors elastase, casein protease, 
and pyocyanin (79), as well as a loss of virulence in a mouse infection model (85). It 
was found that MexAB-OprM transports 3OC12-HSL and is, thus, involved in the las 
signaling pathway (80). The loss of virulence in MexAB-OprM overproducers is 
explained by the decreased intracellular concentration of 3OC12-HSL due to excessive 
efflux (80). Since 3OC12-HSL is no longer able to reach its receptor at high enough 
concentrations, the las pathway is essentially turned off and virulence factors are no 
longer produced (86). This also means that P. aeruginosa strains that acquired 
multidrug resistance through overexpression of MexAB-OprM are deficient in the 
production of virulence factors (79). Hence, MexAB-OprM expression is carefully 
regulated by the rhl signaling pathway, which shows the interconnectedness of quorum 
sensing pathways (87).  
 Another important RND transporter that is involved in signaling is MexEF-
OprN. It was found to transport the PQS precursor HHQ and kynurenine (81, 82). Since 
PQS is required for the expression of several virulence factors (76), overexpression of 
MexEF-OprN was found to result in the loss of virulence, presumably due to the low 
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intracellular concentrations of these PQS precursors (82). Interestingly, this transporter 
was also found to be upregulated in drug resistant clinical isolates of P. aeruginosa 
(42). 
 Lastly, MexGHI-OpmD is also indicated to translocate quorum sensing related 
molecules. Aendekerk et al. found that a disruption in either mexI or opmD resulted in 
reduced levels of key virulence factors like pyocyanin, rhamnolipids, and elastase, as 
well as reduced virulence in a mouse infection model (83, 88). The authors attributed 
these effects to the transporter’s involvement in efflux of the PQS precursor anthranilate 
(83). Another group found that MexGHI-OpmD transports the phenazine 5-
methylphenazine-1-carboxylate (5-Me-PCA), a direct precursor of pyocyanin and 
indicated to be involved in biofilm formation (84). Although RND transporters are most 
notorious for their involvement in multidrug resistance, they play key roles in 
establishing homeostasis of several important molecules. More research has to be 
dedicated to elucidate the involvement of the twelve RND transporters of P. aeruginosa 










Transporters in P. aeruginosa 
RND 
Transporter Substrates References 
MexAB-OprM FQ, ML, TET, LM, CF, NB, PEN, 3O12-HSL (QS) (89, 90) 
MexXY-OprM FQ, ML, TET, LM, CF, AG (89) 
MexCD-OprJ FQ, ML, TET, LM, CF, NB, PEN, CEF (89) 
MexEF-OprN FQ, CF, TMP, TET, HHQ (QS), KY (QS) (81, 82, 91, 92) 
MexGHI-OpmD FQ, EtBr, ACR, Va2+, AN (QS), 5-Me-PCA (QS) (83, 88, 93) 
MexJK-
OprM/OpmH FQ, ML, TET, TRI (94, 95) 
MexMN-OprM CF, TML (96) 
MexPQ-OpmE FQ, ML (96) 
MexVW-OprM ACR, CF, EtBr, ML, FQ, TET (97) 
MuxABC-
OpmB NB, ATM (98) 
TriABC-OpmH TRI, SDS (68, 99) 
CzcCBA Cd2+, Zn2+ (100, 101) 
 
Table I.1 - Substrate specificities of RND transporters in P. aeruginosa. 
3OC12-HSL N-(3-oxododecanoyl)-L-homoserine lactone (QS), 5-Me-PCA 5-
methylphenazine-1-carboxylate (QS), ACR acriflavine, AG aminoglycosides, AN 
anthranilate (QS), ATM aztreonam, CEF cephalosporins, CF chloramphenicol, FQ 
fluoroquinolones, KY kynurenine, LM lincomycin, ML macrolides, NB novobiocin, 
PEN penicillins, SDS sodium dodecyl sulfate, TET tetracycline, TML thiamphenicol, 







I.8 Specific aims and goals of this dissertation 
 Outer membrane permeability represents one of the biggest hurdles in the drug 
screening process (5). Potential hits are often overlooked due to their inability to cross 
the cell envelope. This results in a dramatically reduced amount of chemical structures 
with potentially good antibiotic activity that could be refined to improve their 
permeability. Some methods exist to permeabilize the outer membrane, for example, the 
use of polymyxins. Polymyxins are cyclic peptides attached to a fatty acid chain (102). 
The peptides are basic and, under physiological conditions, carry a positive charge 
(103). This allows them to intercalate into the outer membrane, thereby replacing 
calcium and magnesium ions, disrupting and, effectively, permeabilizing the outer 
membrane (103). At higher concentrations, polymyxins further insert themselves into 
the inner membrane, which results in leakage of essential cytoplasmic components 
leading to cell death (102). Polymyxins were found to potentiate the activity of some 
antibiotics, although this effect is mostly seen in hydrophobic antimicrobials (102). In 
addition to only selectively increasing permeability, they also change the physical 
properties of the outer membrane through their high charge density (102). This makes 
them less ideal in a drug screening approach, where non-selective permeability with an 
intact outer membrane is required. 
 One aim of this dissertation is to describe and characterize a new approach to 
permeabilize the outer membrane using a genetically engineered outer membrane pore 
from E. coli. The gene expressing this pore was inserted into the chromosome of E. coli 
and P. aeruginosa strains and leads to non-selective increase in the permeability of the 
outer membrane. Expression of the pore does affect some of the phenotypes controlled 
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by quorum sensing in P. aeruginosa and increases the uptake of several compounds and 
antibiotics. Furthermore, this dissertation aims to classify groups of antibiotics by 
whether their accumulation into the cell is limited by active efflux, outer membrane 
permeability, or a combination of both. To achieve this, antibiotic susceptibilities were 
tested in strains expressing the pore, lacking efflux, or both and are compared to wild 
type strains. This approach highlights the differences in outer membrane permeability of 
E. coli and P. aeruginosa and defines antimicrobial characteristics that lead to better 
uptake into cells. 
 Furthermore, this dissertation aims to characterize the RND transporter 
MexGHI-OpmD from P. aeruginosa on its contribution to antibiotic resistance and 
physiology. MexGHI-OpmD is an unusual transporter due to its fourth component 
MexG. MexG is a small about 16 kDa protein that is proposed to be located in the inner 
membrane. The function of MexG and whether or not it physically associates with the 
transporter is unknown. MexGHI-OpmD has been indicated to be involved in the 
transport of quorum sensing molecules, and was also found to export the toxic 
pyocyanin precursor 5-methylphenazine-1-carboxylate (5-Me-PCA) (83, 84, 88). 
Pyocyanin is one of the most important virulence factors in P. aeruginosa and is 
responsible for the characteristic blue-green color of P. aeruginosa cultures. A 
disruption in mexI or opmD was also shown to result in a complete loss of virulence in 
PA14; however the mechanism by which MexGHI-OpmD is involved in virulence is 
not known (83). This dissertation aims to elucidate whether MexG is part of the MexHI-
OpmD complex and to understand the transporters role in physiology of P. aeruginosa. 
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II. Materials and Methods 
Table II.1 - List of bacterial strains used in these studies 
Escherichia coli 
Strains Description Source 
BW 25113 
Wild-type strain Δ(araD-araB)567 Δ(rhaD-rhaB)568 
ΔlacZ4787 (::rrnB-3) hsdR514 rph-1 
(104) 
GD102 BW25113 ΔtolC-ygiBC (105) 
GKCW101 
(WT) 
































Strains Description Source 
PAO1 Wild type 
Gift from O. 
Lomovskaya 
PAO1Δ3 PAO1 ΔmexAB ΔmexCD ΔmexXY 
Gift from O. 
Lomovskaya 
PAO314 PAO1 ΔmexAB-oprM ΔmexCD-oprJ ΔmexJKL (95) 
PAO325 









PAO1 ΔmexAB-oprM ΔmexCD-oprJ ΔmexEF-oprN 




PAO1 attTn7::mini-Tn7T-Gm-lacIq-pLAC-MCS (107) 
GKCW112 
(PΔ3) 
PAO1Δ3 attTn7::mini-Tn7T- Gmr-lacIq-pLAC-MCS (107) 
GKCW113 
(PΔ4) 
PAO325 attTn7::mini-Tn7T- Gmr-lacIq-pLAC-MCS (107) 
GKCW114 
(PΔ6) 
PAO1116 attTn7::mini-Tn7T-Gm-lacIq-pLAC-MCS (107) 
GKCW127 
(P∆3S) 

































PAO1 ΔmexGHI-opmD-scar This study. 
DW102 
(P∆3∆G) 
PAO1Δ3 ΔmexGHI-opmD-scar This study. 
DW103 
(P∆4∆G) 
PAO325 ΔmexGHI-opmD-scar This study. 
DW104 
(P∆6∆G) 
PAO1116 ΔmexGHI-opmD-scar This study. 




















Table II.2 - List of plasmids used in these studies 
Plasmids Description Source 
pBSPII (SK-) Cbr; broad-host-range cloning vector (108) 












pMexG Cbr; pBSPII mexG; Blar; expresses MexGHis This 
study. 
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pMexGH Cbr; pBSPII mexG; Blar; expresses MexGHis This 
study. 
pMexGHI Cbr; pBSPII mexGHI; Blar; expresses MexGHIHis This 
study. 








pMexGΔHW Cbr; pBSPII mexG; Blar; expresses MexGΔHWHis This 
study. 
pEX18Ap Apr; oriT+ sacB+, gene replacement vector (109) 
pUC18-mini-
Tn7T-LAC 
Gmr; mini-Tn7T based suicide vector (110) 




pEXdGHI-D pEX18Ap-Gm with upstream and downstream 
fragment of mexGHI-opmD flanking FRT-Gmr-FRT 
This 
study. 




containing fhuA ∆C/∆4L gene 
(106) 





 Unless otherwise indicated, bacterial cultures were grown in Luria-Bertani (LB) 
broth (10 g Tryptone, 5 g Yeast Extract, and 5 g NaCl per liter at pH 7.0) at 37°C and 
shaking at 200 RPM. Optical densities were measured utilizing a UV-1601 (Shimadzu). 
Cultures with OD600 above 1.0 were diluted down before the final OD was determined. 
 
Plasmid construction 
 Sequences of all primers can be found in Appendix A. Plasmid constructs for the 
expression of MexEF-OprN and MexGHI-OpmD were constructed using the broad-
host-range vector pBSPII (SK-) (108). Genes were PCR amplified from PAO1 genomic 
DNA, extracted using the GenElute Bacterial Genomic DNA Kit (Sigma Aldrich), and 
amplified using the primers EFNpbspFWD and EFNpbspREV, or GHIDpbspFWD and 
GHIDpbspREVhis. PCR fragments and the vector pBSPII were digested with KpnI-HF 
and HindIII-HF for MexEF-OprN, or HindIII-HF and BamHI-HF for MexGHI-OpmD 
using the conditions recommended by the manufacturer of the restriction enzymes 
(NEB), and ligated into the digested vector using T4-Ligase (NEB). Ligation of the 
vector with PCR fragments was done following the manufactures protocol. The 
constructs were confirmed by restriction analysis and expression was validated using 
the methods described below.  
 Other parts of the MexGHI-OpmD transporter were cloned into pBSPII (SK-) 
utilizing similar methods utilizing the restriction enzymes HindIII-HF and BamHI-HF 
(NEB). pMexG, pMexGH, and pMexGHI were constructed using the primers 
GHIDpbspFWD and GpbspREVhis, GHpbspREVhis, and GHIpbspREVhis 
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respectively. pMexHI-OpmD was cloned using the primers HIDpbspFWDhis and 
GHIDpbspREVhis. Constructs containing a N-terminal FLAG tag of mexG were 
created using the forward primer GpbspFWDflag and the reverse primer 
GHpbspREVhis for MexGH and GHIpbspREVhis for MexGHI. The MexG mutant 
MexGΔHW was created by site-directed mutagenesis using the QuikChange Lightning 
Kit (Agilent) and the primers GdHWfwd and GdHWrev as per the instructions given by 
the manufacturer. 
 The plasmid pEXdGHI-D was constructed in order to remove mexGHI-opmD 
from the chromosome of P. aeruginosa. pEX18Ap was used as the backbone for the 
construction of the plasmid. The FRT-GMR-FRT cassette from pUC18-mini-Tn7T-LAC 
plasmid was amplified using the primers SalIfrtGMfrtFWD and SalIfrtGMfrtREV, and 
inserted into the multiple-cloning site of pEX18Ap using the SalI restriction site. Next, 
we amplified 500 base pairs directly upstream of MexG using the the primers 
GHIDupFWD and GHIDupREV from PAO1 genomic DNA, and inserted the resulting 
PCR fragment into the created pEX18Ap-GM plasmid using the EcoRI and KpnI 
restriction sites. Similarly, we amplified the last 508 base-pairs of opmD using 
GHIDdownFWD and GHIDdownREV primers and ligated the fragment into the PstI 
and HindIII sites in the pEX18Ap-GM plasmid containing the upstream fragment. The 
result is the pEXdGHI-D P. aeruginosa suicide vector. 
 
Manipulation of chromosomal DNA 
 Gene deletion was carried out using established methods (109). Suicide plasmid 
pEXdGHI-D was transformed into conjugation proficient E. coli SM10 ƛpir donor cells, 
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and cell cultures of SM10 and P. aeruginosa strains were grown overnight to stationary 
phase in Luria-Bertani (LB) broth (10 g Tryptone, 5 g Yeast Extract, and 5 g NaCl per 
liter at pH 7.0). Cells were subcultured 1:100 into fresh LB Media. The media for SM10 
cells harboring the pEXdGHI-D plasmid was supplemented with 10µg/ml gentamicin. 
Both cultures were grown to OD600 of 1.0 and 1ml of each was centrifuged. The pellets 
were resuspended in 50 µl LB media and spotted onto a LB Agar plate. Plates were 
incubated at 37°C overnight to allow for conjugation. Cells were collected, resuspended 
in a 10 mM MgSO4 solution, and plated onto selective Vogel-Bonner minimal media 
agar plates (0.2 g/L MgSO4, 2 g/L citric acid, 10 g/L K2HPO4, 3.5 g/L NaNH4HPO4, 
and 15 g/L agar) (112) supplemented with 15 or 30 µg/ml and 10% sucrose. Colonies 
resistant to gentamicin and sensitive to carbenicillin were further analyzed by PCR to 
confirm successful deletion. To remove the gentamicin resistance cassette, cells were 
transformed with pFLP2 (109) and plated onto 10% sucrose. Colonies were tested for 
carbenicillin and gentamicin susceptibility, and excision was confirmed by PCR. 
 Insertion of the pore was carried out using previously published methods (110). 
P. aeruginosa suicide vector pGK-LAC-FhuAΔC/Δ4L(106) and pTNS2 (111) were 
electroporated into DW104 cells and integration was selected for by plating onto LB 
Agar plates supplemented with 10 µg/m gentamicin. Colonies were confirmed by PCR 
and by vancomycin spot assays as described below. 
 
Minimum Inhibitory Concentration (MIC) Testing 
 MIC determinations were carried out as previously described (113, 114) using 
the 2-fold broth dilution method. Indicated cells were grown with or without plasmids 
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in LB media supplemented with 200 µg/ml carbenicillin at 37°C with shaking at 200 
RPM. Overnight cultures were subcultured 1:100 into fresh media, with antibiotic 
where appropriated, and grown to an OD600 of 1.0 at 37°C with shaking. If protein 
expression is under the control of an inducible promoter, cells were induced at OD600 of 
0.3 with 0.1% L-Arabinose, 0.1 mM, or 2 mM Isopropyl ß-D-1-thiogalactopyranoside 
(IPTG). Cells were subsequently diluted to OD600 of 0.001 into a petri dish containing 
10mL of LB broth. A multichannel pipette was used to inoculate 5x104 cells per 100 µL 
well of a 96-well plate (assuming OD600 of 1.0 equals 109 cells). The plates themselves 
were set up by 2-fold broth dilution using a multichannel pipette to a final volume of 
100 µL of media with antimicrobial at different concentrations. When induction of 
protein expression was required, the media was supplemented with inducer. The last 
row in each plate was left without antibiotic as a control. Once cells were inoculated, 
the plates were left in the incubator at 37°C for 18 hours. The MIC was read by visual 
inspection of the wells and, were indicated, OD600 was read using a 10M Spark 
microplate reader (Tecan).  
 
Spot Assays 
 The spot assays to determine zone of clearance for antimicrobials were carried 
out as previously published (106). Cells were grown to stationary phase in LB media at 
37°C with shaking at 200 RPM and subcultured 1 to 100 into fresh media. The media 
was supplemented with antibiotic where appropriate to ensure that plasmids were 
maintained. Soft agar if prepared by mixing 2 mL of LB with 2 mL of LB Agar (10 g 
Tryptone, 5 g Yeast Extract, 5 g NaCl, and 15 g Agar per liter at pH 7.0) and kept at 
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55°C to prevent the agar from solidifying. IPTG was added to the soft agar at a 
concentration of 0.1mM as necessary for protein expression. Where appropriate, cells 
were induced at OD600 of 0.3 with 0.1 mM IPTG and grown to OD600 of 1.0. 300 µL of 
cultures were taken and mixed with the soft agar. The mixture was poured over LB agar 
plates and allowed to solidify at room temperature. Sterilized filter disks were added to 
the plates and the antimicrobial was spotted onto the disks. The plates were stored 
upside down at 37°C for 18 hours. After this time, the plates were taken out and the 
zones of clearance determined. To confirm the expression of the pore 100 µg of 
vancomycin was spotted onto the disk. For PMS and pyocyanin assays 0.5 and 0.05 
µmoles were spotted respectively. 
 
Determination of Growth Curves and Growth Rates 
 Stationary phase cells were subcultured 1:100 and grown in LB media with 
antibiotic to maintain plasmids were required at 37°C with shaking at 200 RPM. When 
protein induction was necessary, the cultures were induced at OD600 of 0.3 with 0.1% L-
Arabinose or 0.1mM IPTG. Once cells reached OD600 of 1.0 they were diluted to OD600 
of 0.001 into a petri dish containing 10 mL of LB media. Growth was measured in a 96-
well plate by inoculating 105 cells (assuming 109 cells in 1 ml of OD600 of 1.0) into each 
well containing 200µL of media supplemented with inducer where appropriate. When 
growth curves were desired in the presence of antimicrobial, the drug was added in 2-
fold broth dilution. The plates were read in a Spark 10M microplate reader. The heating 
unit in the reader was set to 37°C and it was programmed to read OD600 every 30 
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minutes for 18 or 24 hours. Before each reading the plate was shaken for 10 seconds in 
orbital mode. 
 The data was imported into Microsoft Excel and each well was normalized to its 
OD600 at time zero hours. Triplicates of each strain were averaged and plotted against 
time in hours. Growth rates were calculated by taking LN(OD600) and plotting it against 
time. Plots can be found in Appendix D. Six time points were selected for the 
determination of the rates based on the coefficient of determination (r2) from the 
steepest part of the graph. 
 
Quantification of Pyocyanin 
Extracellular pyocyanin was quantified using previously published 
spectroscopic methods with the following modifications (115). Cultures were grown in 
LB broth supplemented with 50mM HEPES-KOH buffer pH 7.0 to stationary phase. A 
1 mL aliquot was taken and cells were removed through ultracentrifugation at 
100,000xg at 4°C. 500 µL of chloroform was added to the supernatant and samples 
were vortexed for 1 min. The two phases were separated by centrifugation and the blue 
organic phase was transferred to a new tube. Chloroform was evaporated under nitrogen 
and samples were resuspended in 250 µL LB broth with 50 mM HEPES-KOH pH 7.0. 
The absorbance was read at 690 nm and the concentration of pyocyanin was calculated 
using the extinction coefficient (4,310 M-1 cm-1).  
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Quantification of Pyoverdine 
 Quantification was done using previously described methods (116). Indicated 
cultures were inoculated into glucose succinate minimal media (GSM) (10mM slucose, 
10 mM succinate, 40 mM NH4Cl, 0.5 mM K2SO4 and 0.4 mM MgSO4) buffered with 
5mM K3PO4 at pH 7.4) and grown overnight at 37°C with shaking. Cells were 
subcultured 1:50 into fresh GSM and grown for 5 hours, after which time the OD600 was 
determined every 30 min. Pyoverdine was determined by removing cells through 
centrifugation and reading the OD400 of the supernatant. The concentration of 
pyoverdine was calculated using the extinction coefficient of 20,000 M-1 cm-1. The data 
was divided by the OD600 and normalized to PAO1. 
 
Quantification of Biofilm 
 Biofilm accumulation of cells grown for several days was quantified as 
previously described (117). Strains were inoculated into LB media and grown overnight 
to stationary phase. Cells were washed twice with M9 minimal media supplemented 
with 0.4% glycerol, 0.4% casamino acid, and 0.1 mM IPTG to induce expression of the 
pore, and subsequently subcultured 1:100 using the same media into a 96-well PVC 
plate. Plates were incubated at 37°C for 3 days. 20µl of a 0.1% crystal violet was added 
to each well to stain the biofilms and incubated for 15 minutes. Wells were 
subsequently washed rigorously with PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2PO4, 1.8 mM KH2PO4) and allowed to dry. 200 µl of 95% ethanol was added and 
the OD600 was determined. The data was normalized to PAO1. 
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Uptake of Radiolabeled Compounds 
 Cells grown to stationary phase were subcultured 1:100 into fresh LB media and 
incubated at 37°C with shaking at 200 RPM. Expression of the pore was induced with 
0.1% L-arabinose in E. coli and 0.1 mM IPTG in P. aeruginosa strains at OD600 of 0.3. 
Cultures were subsequently grown to OD600 of 1.0 and collected by centrifugation at 
3,220xg for 10 minutes at room temperature. Cells were washed twice in PMG buffer 
(50 mM potassium phosphate, 1 mM magnesium sulfate, and 0.4% glucose at pH 7.0) 
and finally resuspended in PMG buffer of one tenth of the original culture volume. 
 Radiolabeled [14C]-erythromycin was diluted and mixed with cold stock of the 
antibiotic to achieve the desired stock concentration and specific activity of 0.025 
Ci/mmol. The stock was diluted to different concentrations with PMG buffer at 10X the 
final concentration. 100 µL of each concentration was added to 1mL of cells and 
aliquots of this reaction mixture was taken at the indicated time points. The aliquots 
were added to 96-well MultiScreenHTS FB filter plates with 1.0 and 0.65 µm pore sizes 
(EDM Millipore) that were attached to a MultiScreen HTS vacuum manifold (EDM 
Millipore) under vacuum. Before cells were added each filter was treated with PMG 
buffer. The plates were dried overnight and subsequently added to scintillation vials 
each with 2mL scintillation fluid. Radioactivity was determined with a Tri-Carb 
2810TR scintillation counter (PerkinElmer). The samples were normalized to the 0.5-
minute time point and intracellular concentration was calculated assuming OD600 equals 
1 x 109 cells per milliliter and each cell having an average volume of 1µm3. 
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Uptake of Hoechst33342 into Gram-Negative Bacteria 
 Stationary phase cells were subcultured 1 to 100 and grown at 37°C with 
shaking at 200 RPM with antibiotic if appropriate. At OD600 of 0.3 cells were induced 
and grown to and OD600 of 1.0, at which time they were collected by centrifugation at 
3,220xg and room temperature. Pellets were washed twice with HMG buffer (50 mM 
Hepes-KOH, 1 mM MgSO4, and 0.4% Glucose at pH 7.0). Cells were resuspended in 
HMG buffer to an OD600 of 2.0 equivalent for E. coli and 1.0 for P. aeruginosa. 
 The uptake experiment was carried out in a 10M Spark microplate reader 
(Tecan). For this purpose, 100 µL of Hoechst33342 (HT) was distributed into a low 
binding F-bottom 96-well plate (Greiner Bio-One, inc) at 2-fold increasing 
concentrations. The temperature in the plate reader was kept constant at 25°C and 100 
µL of cells were injected into each well. The final concentration of cells in the wells 
were OD600 of 1.0 for E. coli or 0.5 for P. aeruginosa. Fluorescence was measured for 
HT at 460 nm (excitation at 355 nm) every 20 seconds for 10 minutes. The plates were 
shaken briefly before each reading in orbital mode. 
 
Analysis of Fluorescence Uptake Data 
 The data was first plotted in Microsoft Excel and duplicates of an experiment 
were averaged. Fluorescence was normalized to the last time point before cells were 
added and the data was inspected for outliers. To calculate initial rates and steady states 
of fluorophore uptake, the time courses were imported into MATLAB (MathWorks). 
The fittype function was used to fit the data to an exponential equation in the form of: y 
= A1 + A2 * (1 – exp(-k2 * t)). The following constraints were used: For A1 the lower 
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and upper bounds were set to be within 5% of the first point after addition of cells, for 
A2 the lower bound was set to zero and the upper bound to 10% of the last time point 
taken, for k2 the lower bound was set to zero and the upper bound set to one. The start 
point for A1 was equal to the first time point after injection of cells, for A2 was set to the 
last time point, and for k2 was set to 0.01. The fitted lines were plotted in MATLAB and 
the quality of the fit was determined by visual inspection and analysis of the confidence 
intervals as well as the R-squared value of the calculated parameters. 
 To calculate the concentration of intracellular HT a conversion factor was 
determined using the fluorophore binding to salmon sperm DNA or phospholipids. 
These emission coefficients were determined by linear regression of emission of the 
fluorophore plotted against its total concentration. The experiments were carried out 
assuming that 1mL of OD600 1.0 cells contain about 17 µg of DNA and 27 µg of total 
lipids. Once relative fluorescent units (RFU) were converted to the intracellular 
concentration of fluorophore in µM the steady states were determined by simple 
addition of A1 and A2. The initial rates of uptake were determined by multiplying A2 by 
k2. This is justified according to this simple derivation: 
𝑦 = 𝐴$ + 𝐴& ∗ 1 − 𝑒+,-∗.  
𝑑𝑦
𝑑𝑡 = 𝐴& ∗ 𝑘& ∗ 𝑒
+,-∗. 
Since the initial rate is at t = 0: 
𝐼𝑛𝑖𝑡𝑖𝑎𝑙	𝑅𝑎𝑡𝑒 = 𝐴& ∗ 𝑘& 
Unless otherwise indicated, three independent experiments were averaged and the 
standard deviation calculated per fluorophore and strain. 
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Protein Expression and Determination of Concentration of HIS-tagged Membrane 
Proteins 
 Expression of membrane proteins was verified by previously published methods 
(57) with subsequent immunoblotting. Cells grown to stationary phase were subcultured 
1:100 into fresh media supplemented with antibiotic where necessary and grown at 
37°C with shaking at 200 RPM. When induction of proteins was required, cells were 
induced at OD600 of 0.3 with 0.1 mM or 2.0 mM IPTG and grown for 3.5 hours after 
induction. If no induction was necessary, cells were grown for 6 hours after 
subculturing. Cells were collected by centrifugation at 3,220xg and 4°C and pellets 
were stored at -80°C overnight. 
 The pellets were thawed on ice and resuspended in lysis buffer (10 mM Tris-Cl, 
5 mM EDTA, and 100 µg/mL Lysozyme at pH 8.0). The mixture was incubated on ice 
for 1 hours. Cells were further lysed by sonication on ice until the solution became 
clear. Broken cells were separated from whole cells by centrifugation at 3,220xg for 10 
minutes. The supernatant was transferred to a new tube and membrane fractions were 
isolated by ultracentrifugation at 100,000xg for 1 hour at 4°C. The pellet was 
resuspended in resuspension buffer (10 mM Tris-Cl, 150 mM NaCl, and 1 mM PMSF at 
pH 8.0). Protein concentration was determined using a Bradford Protein Assay (Bio-
Rad). Samples were prepared for SDS-PAGE and subsequent immunoblotting by 
normalizing the amount of protein loaded into each lane (either 7.5, 15, or 22.5 µg of 
total protein) of the gel.  
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Purification of FhuAΔC/Δ4LHIS from P. aeruginosa and Determination of Copy 
Number 
 Cells with fhuAΔC/Δ4L chromosomal integrations were grown to stationary 
phase and subcultured 1 to 100 into 1 L of fresh LB broth at 37°C with shaking at 200 
RPM. Cultures were induced at OD600 of 0.3 with 0.1 mM IPTG and grown for 3.5 
hours after induction, after which time the OD600 was recorded. Cells were collected at 
3,220xg at 4°C and washed once in 40 mL of 10 mM Tris-Cl pH 8.0. Cell pellets were 
stored at -80°C until the next day. Samples were thawed on ice and subsequently 
resuspended in 50 mM Tris-Cl, 1 mM MgCl2, 100 µg/mL lysozyme, and 100 µg/mL 
DNaseI. The lysis mixture was incubated on ice for 30 minutes before adding 5 mM 
EDTA at pH 8.0 and an additional incubation for 30 minutes on ice. Samples were 
sonicated until the solution became clear and unbroken cells were separated from lysed 
cells by centrifugation at 3,220xg for 20 minutes at 4°C. Membrane fractions were 
isolated from the supernatant by ultracentrifugation at 100,000xg for 1 hours at 4°C. To 
enrich the outer membrane fraction, the membrane pellet was resuspended in 50 mM 
Tris-Cl, 150 mM NaCl, 1 mM PMSF, 5 mM Imidazole, and 0.2% Triton X-100 at pH 
8.0 and incubated at 4°C overnight while rotating. Outer membranes were isolated by 
centrifugation at 100,000xG and the pellet was solubilized again in 50 mM Tris-Cl, 150 
mM NaCl, 1 mM PMSF, 5 mM Imidazole, and 5% Triton X-100 at pH 8.0 overnight 
with rotating. Insoluble cell debris and proteins were separated from soluble outer 
membrane fractions by ultracentrifugation at 100,000xG for 1 hour at 4°C.  
 The supernatant was incubated for 2 hours with His•Bind Resin (Novagen) at 
4°C with rotating. The resin was previously charged with 50 mM CuSO4 and 
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equilibrated with binding buffer (20 mM Tris-Cl, 500 mM NaCl, 1 mM PMSF, 0.2% 
Triton X-100, and 5 mM Imidazole at pH 8.0). The samples were transferred to a mini 
gravity flow column and washed with 10 column volumes of binding buffer with 5 mM 
and 20 mM Imidazole. FhuAΔCΔ4L was eluted with binding buffer containing 400 mM 
Imidazole at pH 8.0 into 5 fractions of 1 column volume. Elution fractions were 
concentrated with a Microcon-30 kDa (EMD Millipore) and loaded onto a SDS-Page 
gel with subsequent immunoblotting. For detection of FhuAΔCΔ4L a primary 
monoclonal anti-6xHIS antibody (Fisher Scientific) and a secondary anti-Mouse 
alkaline phosphatase conjugated antibody (Sigma Aldrich) was used. 
 To determine the copy number of FhuAΔCΔ4L a protein standard of a P. 
aeruginosa membrane protein (TriCHIS) was loaded onto the same gel at 2-fold 
increasing concentrations. To estimate the amount of FhuAΔCΔ4L the Quantity One 
software (Bio-Rad) was used. After determination of the amount of protein, the copy 
number was calculated under the assumptions that 1mL of cell culture at OD600 contains 
1x109 cells and 100% of the pore bound and eluted from the column.  
 
Protein Crosslinking Experiments 
For chemical crosslinking assays, PΔ3 cells expressing pMexGHI-flag or 
pMexGH-flag were harvested by centrifugation. Pellets were washed twice in PBS 
buffer (8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, 0.24 g/L KH2PO4 at pH 7.4) and, 
subsequently, 4 mM DSP (dithiobis(succinimidyl propionate)) or DMSO was added to 
samples and controls respectively. Cells were allowed to incubate for 2 hours at 37°C 
while rotating. The reaction was quenched with 100 mM Tris-Cl pH 8.0. Cells were 
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harvested by centrifugation and resuspended in 50 mM Tris-Cl pH 8.0, 1mM MgCl2, 
100 µg/ml DNAseI, and 100 µg/ml Lysozyme. The lysis mixture was incubated on ice 
for 30 min. EDTA was added to the samples to a final concentration of 5 mM and cells 
were incubated for an additional 30 min on ice. Lysis was completed by sonication and 
unbroken cells were separated from broken cells by centrifugation. Membrane fractions 
were isolated by ultracentrifugation at 100,000xg at 4°C for 1 hour. Pellets were 
resuspended in 50 mM Tris-Cl, 150 mM NaCl, 5 mM Imidazole, 1 mM PMSF, and 5% 
Triton X-100 at pH 8.0 and incubated at 4°C overnight while rotating. Soluble 
compounds were separated from insoluble ones by centrifugation at 100,000xg at 4°C 
for 1 hour. His-tagged proteins were purified with His•Bind Resin (Novagen), 
previously charged with 50mM CuSO4. Samples were eluted from the column with 20 
mM Tris-Cl, 500 mM NaCl, 1 mM PMSF, 0.2% Triton X-100, and 500 mM Imidazole 
at pH 8.0. Samples were subsequently analyzed by SDS-PAGE and immunoblotting 
onto polyvinylidene fluoride membranes (Santa Crux Biotechnology) with Anti-His 
(Invitrogen) or Anti-FLAG (Agilent) primary antibodies followed by secondary Anti-
Mouse antibody (Sigma Aldrich) conjugated with alkaline phosphatase. The membranes 
were developed with 5-bromo-4-chloro-3-indoyl phosphate (BCIP) and nitroblue 
tetrazolium (NBT). 
 
Purification of MexGHIS from P. aeruginosa 
 PΔ3 cells carrying the pMexG plasmid were grown to stationary phase at 37°C 
with 200 µg/ml carbenicillin and subsequently subcultured 1:100 into fresh media 
supplemented with drug. Cultures were grown for 18 hours at 37°C with shaking at 200 
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RPM and collected by centrifugation at 3,220xg at 4°C for 40 minutes. Pellets were 
washed once in 10 mM Tris-Cl pH 8.0 and stored at -80°C until the next day. Cells 
were allowed to thaw on ice and resuspended in lysis buffer (50 mM Tris-Cl, 1 mM 
MgCl2, 100 µg/ml lysozyme, and 100 µg/ml DNaseI at pH 8.0). The lysis mixture was 
incubated on ice for 30 minutes, after which time EDTA (pH 8.0) was added to a final 
concentration of 5mM and samples were incubated for another 30 minutes on ice. To 
complete lysis, cells were sonicated until the solution became clear and unbroken cells 
were separated by centrifugation at 3,220xg and 4°C for 10 minutes. Membrane 
fractions were isolated by ultracentrifugation at 100,000xg and the pellet was 
resuspended in solubilization buffer (50 mM Tris-Cl, 150 mM NaCl, 1 mM PMSF, 5 
mM Imidazole, and 2% n-Dodecyl-β-D-maltoside (DDM) at pH 8.0). The solubilization 
mixture was incubated at 4°C with rotating for 18 hours. Insoluble cell debris was 
removed by ultracentrifugation at 100,000xg and 4°C for 1 hour and the supernatant 
was applied to His•Bind Resin (Novagen) of 500 µL. The concentration was determined 
by SDS-PAGE with a BSA protein standard and subsequent analysis with Quantity One 
(Bio-Rad). 
 
Fluorescence Binding Assay 
Fluorescence binding assays were carried out with 1µM purified MexG in 50 
mM Tris-Cl, 500 mM NaCl, 1 mM PMSF, and 0.03% DDM. We used a RF-5301PC 
Spectrofluorophotometer (Shimadzu) and took emission spectra from 300 nm to 550 nm 
with excitation at 290nm. Readings were done in fast mode and excitation and emission 
slits set to 5 nm. All experiments were carried out at 25°C in triplicates. Pyocyanin 
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(Sigma Aldrich) was dissolved in ethanol and titrated into the MexG sample. We 
measured the binding by monitoring the emission at 330 nm. 
Analysis of the fluorescence quenching was done assuming a 1 to 1 binding model as 




𝑃 =>?? ∗ 𝐿 =>??
 (1) 
where 
 𝑃 =>?? = 𝑃 .@.:A − 𝑃𝐿  (2) 
and [𝐿]=>?? = [𝐿].@.:A − [𝑃𝐿]	 (3) 




𝑃 .@.:A − 𝑃𝐿 ∗ ( 𝐿 .@.:A − 𝑃𝐿 )
 (4) 
Solving for [PL] gives: 
 𝑃𝐿 = − 𝐾:








where [P]free and [L]free are the free protein and ligand concentrations; [PL] is the 
concentration of the protein ligand complex; Ka is the association constant; F0 and F are 
the initial fluorescence and the observed fluorescence after addition of ligand; and ΔF is 
the change of fluorescence upon addition of the ligand. 
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 Fluorescence data was first corrected for dilution and inner filter effects as 






















Chapter 1.  Permeabilizing the Outer Membrane of Escherichia coli and 
Pseudomonas aeruginosa 
1.1 Abstract 
 Cases of infections caused by multidrug resistant isolates of human 
pathogens are becoming increasingly more frequent. The current drug discovery 
pipeline is unable to keep up with the fast-evolving resistance in bacteria, and new 
ways to improve it are desperately needed. Gram-negative bacteria represent the 
biggest challenge due to their highly impermeable cell envelope, which results in a 
considerably lower hit rate during screening (5). Approaches to permeabilize the 
outer membrane so far have significant disadvantages, including changing the 
physical properties of the outer membrane and providing a permeability 
preference to hydrophobic molecules (102). Here, we are describing strains that 
contain a chromosomally inserted copy of a genetically engineered pore from E. 
coli. The pore is altered to increase its exclusion size and sensitizes the cells to 
antibiotics traditionally reserved for gram-positive bacteria due to their inability 
to penetrate the gram-negative cell envelope. We show that the expression of the 
pore can controllably increase the outer membrane permeability in E. coli and P. 








 Pseudomonas aeruginosa is an opportunistic, gram-negative human pathogen 
that is most commonly associated with nosocomial diseases, especially infections in 
cystic fibrosis patients. Of particular concern is the increased frequency of multidrug 
resistant clinical isolates of this bacterium, placing it on the top of the list of priorities 
for the development of new antibiotics (3, 6). P. aeruginosa, like other gram-negative 
bacteria, possesses high levels of intrinsic resistance through synergistic effects between 
the low permeability cell envelope and active efflux across the outer membrane. In 
order to study this synergism, the contributions of efflux and the outer membrane 
barrier have to be analyzed separately. Chromosomal deletions of RND transporters 
remove the contributions of efflux to resistance, however there is currently no suitable 
way to remove the contribution of the outer membrane barrier.  
 To date, the methods available to permeabilize the outer membrane, including 
polymyxins, are not ideal for screening, due to the fact that they significantly change the 
physical properties of the outer membrane and favor the uptake of hydrophobic 
compounds (102). Polymyxins are acetylated peptides that are highly positively 
charged. This allows them to displace the divalent ions of the outer membrane, 
intercalating into the membrane, and effectively permeabilizing it (103). Polymyxins 
change the physicochemical properties of the membrane and were shown to increase the 
uptake selectively for hydrophobic molecules (102). This make them less ideal for drug 
screening, where an outer membrane with native properties is desired.  
 We developed a novel way to permeabilize the outer membrane of E. coli and P. 
aeruginosa, leading to an increased uptake of compounds non-selectively. Our approach 
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utilizes a genetically modified version of the outer membrane β-barrel protein FhuA 
from E. coli to hyperporinate the cells in an inducer dependent manner. FhuA or ferric 
hydroxamate uptake component A is a siderophore transporter in E. coli involved in 
iron uptake (Fig. 1.1) (120). The crystal structure of FhuA was solved and it was found 
to consist of 22 antiparallel β-strands forming a β-barrel, four extracellular loops and a 
globular N-terminal cork fold (Figure 1.1) (121). Mohammad et al. engineered the pore 
by deleting the four loops and the cork domain to be used as a biosensor (122). The 
result is an open pore with an average diameter of about 2.4 nm (123). 
 Here, we are describing E. coli and P. aeruginosa strains with a chromosomal 
copy of fhuaΔ4L/ΔC under arabinose or IPTG inducible promoter respectively. This 
approach allows us to control the permeability of the outer membrane by changing the 
inducer concentration. Our findings show that the pore non-selectively increases the 
antibacterial activities of several antibiotics, while not impacting cell viability. We 
show that expression of the pore sensitizes both species to vancomycin, a drug that is 
thought to be unable to penetrate the outer membrane, and increases uptake of 
radiolabeled antibiotics. Furthermore, through a combination of strains expressing the 
pore, lacking major RND transporters, or both, we are able to determine the extent to 
which active efflux or outer membrane permeability plays a role in providing antibiotic 
resistance. Traditionally, it has always been a challenge to isolate the contribution of 
efflux on the level of resistance it provides due to the presence of and synergy with the 
outer membrane. Using this approach, we are able to isolate efflux from the outer 
membrane permeability barrier and individually analyze its contribution on resistance. 
The strains described here can provide useful tools for drug screening and provide 
51 
information needed to help discover molecular characteristics that more easily allow 





Figure 1.1 - Crystal structure of the siderophore transporter FhuA from E. coli. 
FhuA crystal structure from PDB: 1BY3 (Locher, et al. (124)). Regions in red show the 
deleted cork domain and the 4 extracellular loops in the mutant pore FhuAΔ4L/ΔC 
(122). The mutant pore has an average diameter of 2.4nm (123). A: Side view and B: 





1.3.1 Controlled expression of the pore permeabilizes the cell envelope of E. coli 
and P. aeruginosa  
 The strains described here expressing the E. coli pore mutant FhuaΔ4L/ΔC 
(from here on referred to as “pore”) were cloned as described in the published 
manuscript for E. coli (106) and the submitted manuscript for P. aeruginosa (107). The 
gene fhuaΔ4L/ΔC was inserted into several E. coli and P. aeruginosa strains that differ 
in their efflux proficiency. For E. coli, we used BW25113 as a reference strain and the 
tolC deletion mutant GD102 (105) (referred to as ΔTolC). Deletion of tolC in E. coli 
results in the loss of function of at least nine transporters and renders the strain largely 
efflux deficient (55, 72). For P. aeruginosa, we chose several efflux deficient mutants 
of PAO1 for insertion of the pore. We chose PAO1 as our wild type due to its frequent 
usage in laboratories and its low virulence compared to other P. aeruginosa strains. P. 
aeruginosa contains at least 12 RND transporters on its chromosome and most of them 
are in an operon together with their own OMF. In contrast to E. coli’s TolC, no single 
OMF is exclusively used by several transporters, making it much more challenging to 
create an efflux deficient variant of PAO1. To this end we used PAO1 (Gift from Dr. O. 
Lomovskaya), PΔ3 (ΔmexAB ΔmexCD ΔmexXY) (Gift from Dr. O. Lomovskaya), PΔ4 
(95) (ΔmexAB-oprM ΔmexCD-oprJ ΔmexJKL ΔmexXY), and PΔ6 (99) (same as PΔ4, 
but also ΔmexEF-oprN ΔtriABC). Using this step-wise approach of efflux deficient 
strains, we expect to see the contributions of “minor” efflux pumps on the antibiotic 
resistance profile of P. aeruginosa. In addition, step-wise deletion might also highlight 
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differences in the production of virulence factors and quorum signals in pore strains 
when certain transporters are deleted. 
 We checked the expression of the chromosomal integration in E. coli by 
isolating membrane fractions and subsequent analysis with immunoblotting. The pore 
carries a C-terminal 6xHis tag allowing us to detect it using primary anti-his antibodies 
(Fisher Scientific) and subsequent incubation with secondary anti-mouse (Sigma 
Aldrich) antibodies conjugated with alkaline phosphatase. The immunoblot in Figure 
1.2A shows the expression of the mutant pore in WT (BW25113) and the efflux 
deficient ΔTolC (BW25113 ΔtolC ΔygiBC) strain. Furthermore, hyperporination can be 
controlled by varying the concentration of arabinose as seen in Figure 1.2B and C. We 
are not able to detect the pore at either zero or 0.0001% of the inducer, suggesting that 
the pore is under tight control of the promoter. Increasing the arabinose concentration 
shows a positive correlation with the copy number of the pore. Utilizing the previously 
purified and quantified membrane protein TriCHis as a standard, we were able to 
calculate the expression of the pore to about 150 copies per cell at 0.1% arabinose in 
WT. 
 In the P. aeruginosa strains, quantifying the pore protein was more challenging. 
Since we noticed significant leaky expression from the arabinose promoter, we decided 
to use strains with the pore under the control of an IPTG inducible promoter. We were 
unable to detect the FhuA mutant to any significant levels in whole membrane fractions 
or even enriched outer membranes, suggesting that expression is either much lower than 
in E. coli, the pore is not properly inserted into the outer membrane, or the C-terminal 
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sequence of the pore, where the Histidine tag is located, is recognized and cleaved as a 
signal peptide.  
 To test whether the protein is expressed at low levels, we grew larger culture 
volumes and added the isolated outer membrane fractions to metal affinity columns to 
purify and concentrate the pore and remove the bulk of other outer membrane proteins. 
After purification, we concentrated the elution fractions further using mini centricons 
and, subsequently, analyzed the samples by immunoblotting. The results can be seen in 
Figure 1.2D. The immunoblot shows the pore is expressed in PAO1 and all four efflux 
deficient mutants albeit at low amounts. Quantification with the TriCHis standard 
resulted in roughly 5-7 copies per cell in PAO1-Pore, about 2 copies for PΔ3-Pore, 
about 1.5 copies for PΔ4-Pore, and about 1 copy per cell of PΔ6-Pore at 0.1 mM IPTG. 
These calculations were done assuming that the pore binds the affinity resin to 100% 
and that an OD600 of 1.0 equals 109 cells per milliliter. These results of the expression in 





Figure 1.2 - Expression of the Pore in E. coli and P. aeruginosa. 
The expression of FhuAΔC/Δ4L is inducer dependent and higher in E. coli than in P. 
aeruginosa. A: Expression in E. coli WT and ΔTolC induced with 0.1% arabinose. C 
shows expression of WT without a chromosomal copy of the pore. B and C: Arabinose 
dependent pore expression in E. coli WT-Pore cells. The pore was quantified using a 
His-tagged protein standard, and copy number estimated by assuming OD600 of 1.0 
equals 109 cells per ml. Expression in E. coli was done by Dr. Ganesh Krishnamoorthy. 
A-C are modified from published figure (106). D: Pore expression is dependent on 
inducer (IPTG) concentration in P. aeruginosa. The pore was purified using metal 
affinity chromatography. 
56 
 To check whether the expression of the pore correlates with increased 
susceptibility and permeability, we tested our constructed strains for vancomycin 
susceptibility using filter disk assays. Vancomycin is a large antibiotic with a molecular 
weight of about 1,449.3 Da that inhibits the synthesis of peptidoglycan, and is widely 
used against infections caused by gram-positive bacteria (Fig. 1.3C). However, its large 
size typically precludes it from activity in gram-negative bacteria, due to its inability to 
permeate the outer membrane. The results of the spot assays can be seen in Figure 1.3A 
and B. As seen by the larger diameters, only pore strains of both E. coli and P. 
aeruginosa that were induced by either arabinose or IPTG showed significant 
susceptibility to vancomycin. The control strains, with insertion of the respective 
promoter and empty multiple cloning site, did not change susceptibilities with addition 
of inducer, and the zones are comparable to the pore strains without inducer. This 
suggests that the pore is functionally expressed and that it sensitizes strains to 
vancomycin that otherwise is not able to cross the outer membrane. Thus, the FhuA 
mutant has a significantly larger exclusion size as the general porins in E. coli and P. 
aeruginosa, increases susceptibility of the strains tested to antibiotics, and its expression 









Figure 1.3 - Expression of the pore sensitizes gram-negative bacteria to 
vancomycin. 
The pore increases the susceptibility of E. coli (A) and P. aeruginosa (B) to 
vancomycin. The drug was spotted onto plates that were seeded with the respective 
strains and incubated for 18 hours at 37°C. Large zones of clearance highlight the 
increase in susceptibility. C: Structure of vancomycin. The susceptibility is controlled 
by 0.1% arabinose or 0.1 mM IPTG respectively. Experiments were carried out by Dr. 
Ganesh Krishnamoorthy. E. coli results are modified from a published figure (106), and 





1.3.2 Hyperporination has a limited effect on physiology 
 In order for the constructed strains to be useful tools to study the contribution of 
the outer membrane to resistance, expression of the pore should not affect the 
physiology of the bacterium in a significant manner. To check if the presence of the 
mutant pore has an impact on growth of the strains, we measured growth curves of each 
strain at increasing concentrations of inducer. In E. coli, we compared growth of strains 
grown in the presence of 0.0001% to 0.1% arabinose in strains with and without the 
pore. We noticed that all strains prematurely reached stationary phase at arabinose 
concentrations of 0.001% and higher (Fig. 1.4). Since this effect is also seen in strains 
that do not have a chromosomal copy of the mutant FhuA, it is not specific to the pore 
strains. However, it does seem to be more pronounced in hyperporinated strains. When 
comparing the pore strains to their respective parental strains, we found a slight 
decrease in the optical densities at 600 nm (OD600) of cell cultures at stationary phase in 
the pore strains. The final OD600 of WT-Pore was about 10% lower compared to WT. 
This effect was slightly bigger for the efflux deficient ΔTolC strains with about a 20% 
decrease of the OD600 at stationary phase for ΔTolC-Pore compared to ΔTolC. 
However, we did not find a significant difference in the growth rates, when comparing 
the hyperporinated to their parental strains. Overall, the E. coli pore strains displayed 







Figure 1.4 - Impact of the pore on growth of E. coli. 
Growth curves of WT (A), WT-Pore (B), ΔTolC (C), and ΔTolC (D) at increasing 
concentrations of inducer. E: Comparison of OD600 at stationary phase. Growth rates 
(F) were calculated by plotting ln(OD600) against time and determining the slope of the 








 For P. aeruginosa, we first analyzed at the growth curves of cells without the 
pore at either no inducer or 0.1 mM IPTG (Fig. 1.5A and B). We noticed a difference in 
the growth of the deep efflux deletion mutants PΔ4 and PΔ6. Compared to the wild type 
PAO1 and PΔ3, their OD at stationary phase was significantly lower by about 40%. 
This difference is likely due to the outer membrane factors which are deleted in PΔ4 
and PΔ6 but are still present in PΔ3. Deletion of OMFs were shown to impact the 
integrity of the outer membrane in E. coli, and similar effects could reduce the OD at 
stationary phase in P. aeruginosa (105). Furthermore, deletion of the RND transporters 
did not seem to have an impact on growth phenotypes when comparing PAO1 and PΔ3, 
suggesting that any differences for the deep efflux deficient mutants is likely the result 
of the missing OMFs. IPTG itself did not affect growth of the P. aeruginosa strains. 
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Figure 1.5 - Growth of PAO1 and efflux deficient variants. 
Comparison of the growth of PAO1 and efflux deletion mutants with no inducer (A) 
and 0.1 mM IPTG (B). There is no significant effect of the inducer on the growth of 
strains without the pore. C: Growth rates of strains at increasing concentration of IPTG. 






 Next, we analyzed the growth phenotypes of hyperporinated P. aeruginosa 
strains (Fig. 1.6). First, we noticed the same decrease in the OD600 at stationary phase 
when the OMFs are deleted. When titrating the inducer, we saw no significant effect up 
to a concentration of 0.01 mM IPTG on the OD600 or the growth rates (Fig. 1.6E). At 
higher inducer concentrations, we noticed an effect of hyperporination on the growth of 
the P. aeruginosa. Cells went to stationary phase prematurely and their final OD600 was 
roughly 50% lower when compared to no inducer (Fig. 1.6A-D). However, this did not 
affect the growth rates of the strains, which remained largely unaffected by the pore 
(Fig. 1.6E). The only exception to this seemed to be PΔ3, which had a significant 
decrease in the growth rates at 0.1 mM IPTG. The least affected strain was PAO1 
which, presumably, can complement the decreased permeability of the outer membrane 
with active efflux.  
 In addition, we noticed that cells expressing the pore started to aggregate at this 
inducer concentration, which could be related to cell signaling. Cell-to-cell 
communication requires the presence of a quorum to produce a high enough 
extracellular concentration of signaling molecules to activate their respective receptors 
(78). It is likely that increasing the outer membrane permeability could reduce this 
concentration threshold. This way, a lower cell density could produce enough signaling 
molecules to activate their respective signaling circuit. Since biofilm formation is 
directly linked to quorum sensing, it is possible that hyperporinated cells start to form 
aggregates at lower cell densities (125). This would explain why the pore expressing 
cells go into stationary phase prematurely and start to form biofilms. To test whether the 
reduced OD600 at stationary phase correlates with a lower number of viable cells, we 
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measured the colony forming units (CFU) directly following a growth curve experiment 
(Fig. 1.6F). We normalized the CFUs to the respective OD600 of the culture, and noticed 
no significant difference between the hyperporinated and the parental strain. This 
suggests that although they go into stationary phase prematurely, the pore expressing 
strains are still healthy and the growth phenotype is likely due to the premature 










Figure 1.6 - Growth phenotypes of cells expressing the mutant FhuA. 
A-D: Growth curves of PAO1-Pore, PΔ3-Pore, PΔ4-Pore, and PΔ6-Pore respectively at 
increasing concentration of inducer. At 0.1 mM, cells enter into stationary phase 
prematurely. E: Growth rates of P. aeruginosa pore strains at increasing concentration 
of inducer. Plots of LN(OD) vs time can be found in Appendix D. F: Colony forming 
units of pore strains per ml and OD600 with and without inducer. Results suggest no 
significant difference in the number of viable cells when the pore is expressed. Error 





 To further analyze the physiological effects of hyperporination in P. aeruginosa, 
we measured the production of pyocyanin, pyoverdine, and the formation of biofilms 
and compared them to their respective strain without the pore. Pyocyanin is a virulence 
factor that is responsible for the blue-green color of P. aeruginosa cultures. Its 
production is directly controlled by the rhl and PQS quorum signaling pathways, and by 
itself can act as a signaling molecule (126, 127). Our measurements show that PAO1-
Pore produces pyocyanin to the same levels as the control without inducer (Fig. 1.7A). 
There is a significant difference between the PAO1 strains and the efflux deficient 
mutants. PΔ3 produces about 73% less pyocyanin when compared to PAO1, with PΔ4 
and PΔ6 synthesizing even less of the virulence factor. The difference between PAO1 
and PΔ3 is likely due to the deletion of MexAB, since this transporter was already 
indicated to be involved in quorum sensing (79, 90). Further decrease of the virulence 
factor suggests that the minor efflux pumps that are absent in PΔ4 and PΔ6 may also 
contribute to cell signaling. The difference between the levels of pyocyanin of PΔ4 and 
PΔ6 is likely due to the deletion of MexEF-OprN, since it is also indicated to transport 
signaling molecules (128). In addition, expression of the pore in efflux deficient strains 
resulted in a further decrease of about 50% of the pyocyanin levels. This suggests that 
the presence of the pore does indeed change some of phenotypes controlled by quorum 
sensing. The fact that we do not observe this decrease in PAO1-Pore suggests that the 
major transporters can complement hyperporination with regard to the synthesis of this 
virulence factor.  
 Pyoverdine is another pigment that is controlled by quorum sensing (129). 
Pyoverdines are siderophores that are necessary in maintaining iron homeostasis in P. 
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aeruginosa(130). When measuring pyoverdine in PAO1 and PΔ4, we were unable to 
detect a significant difference in the production of the siderophore between pore 
expressing strains and their respective parental strains (Fig. 1.7B). Interestingly, we 
noticeed that PΔ4 produces about 50% more pyoverdine than PAO1.  
 Lastly, we measured the production of biofilm in PAO1 and PΔ4 strains with 
and without the pore (Fig. 1.7C). Our results show that PΔ4 produces about 30% more 
biofilm when compared to PAO1. However, expression of the pore did not seem to 
affect biofilm formation. This suggests that although the pore variants initially show 
more cell aggregates and enter the stationary phase prematurely, they ultimately 
produce equal amounts of biofilm compared to their non-pore expressing counterparts. 
Overall, it seems that hyperporination affects the quorum sensing signaling pathways of 
P. aeruginosa to an extent, as seen by the differences in pyocyanin production. 
However, the pathways are not inhibited since other quorum sensing phenotypes are 








Figure 1.7 - Effect of pore expression on phenotypes controlled by cell signaling. 
A: Pyocyanin production in P. aeruginosa pore strains with and without 0.1 mM IPTG. 
Hyperporination decreases pyocyanin synthesis by about 50% in the efflux deficient 
strains. Furthermore, all efflux deficient variants produce significantly less of the 
virulence factor. The pore does not affect pyoverdine production (B) or biofilm 










 Overall, expression of the pore affects both E. coli and P. aeruginosa in a 
similar way. Both organisms go into stationary phase early, although the effect is much 
more pronounced in P. aeruginosa. However, growth rates in both organisms do not 
change significantly and, in the case of P. aeruginosa, the reduction in the OD at 
stationary phase does not affect cell viability. Thus, hyperporination appears to be a 
much gentler way of increasing the outer membrane permeability when compared to, 
for example, the use of polymyxins. 
 
1.3.3 Hyperporination sensitizes E. coli to antibiotics and increases their 
intracellular concentration. 
 Since the presence of the pore increased the sensitivity of all strains to 
vancomycin, we wanted to see whether it would also potentiate smaller antibiotics. To 
test this, we grew E. coli strains with and without the pore at increasing concentrations 
of ciprofloxacin and erythromycin (Fig. 1.8). Ciprofloxacin is a fluoroquinolone that 
inhibits DNA gyrase and topoisomerase IV. Both enzymes are important for DNA 
replication, by cutting double stranded DNA and relaxing positive supercoils. 
Ciprofloxacin is a polar molecule that is relatively small at a molecular weight of about 
about 330 Da. Generally, small polar molecules enter the cells by passively diffusing 
through general porins. Since the exclusion size of the outer membrane porins OmpF/C 
in E. coli is about 600 Da, it should be able to enter cells readily even without the 
addition of the pore (30). Our results show significant change in the minimum 
inhibitory concentration (MIC) between E. coli WT and the efflux deficient ΔTolC 
mutant (Fig. 1.8A). The MIC is defined as the minimum concentration of a compound 
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required to inhibit visible growth of the bacterium. We determined the MIC of 
ciprofloxacin in the WT to be 8-fold greater than in ΔTolC, suggesting that efflux is a 
major contributor of the accumulation of ciprofloxacin into E. coli. There is also a slight 
drop of the optical densities (OD) of the WT-Pore cultures at ciprofloxacin 
concentrations below the MIC. This decrease is not solely due to the physiological 
impact of the pore, since the OD of cultures without ciprofloxacin resulted in only a 
20% decrease for the pore mutant. However, the actual MIC value only decreased by 
two-fold in the pore variant, suggesting that the activity of ciprofloxacin is not 
significantly limited by diffusion across the outer membrane. Furthermore, there was 
also no significant difference in the efflux deficient ΔTolC strain with and without the 
pore. Hence, active efflux is the major determinant of the activity of ciprofloxacin in E. 
coli and the outer membrane barrier only has a minimal impact on the MIC, which is 
likely due to general porins of E. coli. However, the pore inhibits the growth of the WT 
strain at lower, sub-inhibitory concentrations, suggesting that it does increase the uptake 
of the drug.  
 Erythromycin is a large, relatively polar antibiotic with a molecular weight of 
about 700 Da that belongs to the class of macrolides, which bind to the 50S subunit of 
the ribosome and inhibit protein synthesis. Thus, like fluoroquinolones, macrolides need 
to penetrate the outer and inner membrane, but, unlike ciprofloxacin, erythromycin is 
much larger and exceeds the 600 Da cutoff of E. coli’s general porins (30). The 
inhibition curves with erythromycin show a 32-fold change in the MIC when comparing 
WT to ΔTolC, which highlights that efflux transporters are proficient in transporting 
this relatively large antibiotic (Fig. 1.8B). When comparing the WT to the WT-Pore 
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mutant, the MIC decreased from 64µg/ml to 4µg/ml, thus resulting in another 16-fold 
change. This shows that both the outer membrane barrier and active efflux work in 
synergy to provide resistance to this antibiotic. Surprisingly, when comparing the efflux 
deficient ΔTolC to the pore expressing ΔTolC-Pore, we noticed another 4-fold 
reduction of the MIC. A change in the MIC of ΔTolC strains when hyperporinated 
suggests that there is still some efflux present in ΔTolC. Since TolC largely controls 
efflux across the outer membrane, this efflux likely occurs through the inner membrane. 
When comparing the MIC of WT to ΔTolC-Pore, we measured the most significant 
change of 128-fold. Overall, hyperporination and the depletion of efflux affect both 
antibiotics differently. Ciprofloxacin is small and can diffuse trough general porins, thus 
its activity is only limited by efflux and not the outer membrane permeability. On the 
other hand, efflux works synergistically with the outer membrane barrier to limit the 













Figure 1.8 - Growth inhibition of antibiotics in E. coli pore strains. 
Indicated cells were grown in the presence of different concentrations of ciprofloxacin 




MIC in µg/ml Ciprofloxacin Erythromycin 
WT 7.8 64 
WT-Pore 3.9 4 
ΔTolC 0.96 2 
ΔTolC-Pore 0.96 0.5 







 To test whether the increased sensitivity of the pore expressing strains correlates 
with a higher drug uptake, we measured accumulation of [14C]-erythromycin in our 
constructed E. coli strains. For this, we grew cells to early stationary phase with 0.1% 
arabinose to induce expression of the pore, washed them twice with buffer containing 
0.4% glucose to energize the transporters, and incubated them with radiolabeled 
erythromycin at a specific activity of 25 mCi/mmol. From this mixture, we took 
aliquots at different time points and added them to filter disks that were attached to a 
vacuum manifold. The filters were subsequently dried and the radioactivity measured 
using a scintillation counter. The steady state accumulation of the antibiotic was 
estimated by using the intracellular concentration reached after 32 minutes of 
incubation. We noticed that the antibiotic was binding to the filter disks, thus the 
measured absolute values of intracellular antibiotic do not necessarily reflect the actual 
concentration inside the cell. However, comparing relative amounts of uptake still 
yields information about the differences of the strains (Fig. 1.9). 
 Comparing the accumulation of erythromycin in WT and WT-Pore, the 
hyperporination clearly increases the uptake of the drug as seen by a greater 
intracellular concentration of erythromycin (Fig. 1.9A and B). When looking at the 
steady state accumulation plotted against the extracellular erythromycin concentration 
(Fig. 1.9E), the WT strain follows a linear trend with a shallow slope at lower 
concentrations. Once the extracellular concentration is increased beyond 10 µM, we 
begin to see an increase in the slope and a hyperbolic relationship. A hyperbolic pattern 
indicates that at lower concentrations efflux transporters are able to keep the 
intracellular concentrations low. However, once we increase the extracellular 
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erythromycin concentration, high levels of the substrate overwhelm the transporters and 
efflux is becoming less efficient. Thus, the slope increases at higher concentrations of 
the drug. Overall uptake of erythromycin is the lowest in WT, which correlates well 
with the measured MICs of 64 µg/ml. The WT-Pore and ΔTolC showed comparable 
levels of erythromycin accumulation with a linear relationship, which is also reflected 
in a similar MIC value of 2-4 µg/ml. This suggests that hyperporination increases 
periplasmic concentrations of the drug beyond the capacities of the transporters, 
resulting in a similar accumulation of erythromycin in WT-Pore as in the efflux 
deficient strain. Hyperporinating the ΔTolC strain further increases the uptake, 
highlighting that there is significant efflux across the inner membrane (Fig. 1.9C and 
D). This is also in agreement with the overall lowest MIC of 0.5 µg/ml. In addition, the 
data also shows that the intracellular concentration was calculated to be higher than the 
extracellular concentration. This suggests that erythromycin is concentrated inside the 





Figure 1.9 - Uptake of radiolabeled [14C]-Erythromycin in E. coli strains. 
A-D: Time course of accumulation of the drug in WT, WT-Pore, ΔTolC, and ΔTolC-
Pore respectively. Data shown is representative of 3 replicates. E: Steady state 
concentrations of intracellular erythromycin plotted against extracellular concentrations 
of the antibiotic. Steady states were estimated by the uptake after 32 minutes of 







 Overall, the growth inhibition results for erythromycin agree with the uptake 
experiments. The WT had the lowest uptake and correspondingly the highest MIC with 
64 µg/ml. WT-Pore and ΔTolC both had comparable levels of uptake and also have 
similar MICs at 2-4 µg/ml. Growth inhibition and the uptake experiment showed that 
hyperporination of the TolC mutant potentiates the activity of erythromycin by an 
additional 4-fold and also further increased its uptake. These results show that the 
decrease in the MIC in hyperporinated cells directly correlates with increased uptake of 
the antibiotic. Thus, the pore potentiates large antibiotics by increasing their 
intracellular accumulation.  
 
1.3.4 Hyperporination sensitizes P. aeruginosa to small and large antibiotics. 
 To study the effects of hyperporination on drug susceptibility in P. aeruginosa, 
we grew cells in the presence of azithromycin and carbenicillin and monitored the 
optical densities of the cultures. Azithromycin is a macrolide, similar to erythromycin, 
however with somewhat higher potency in P. aeruginosa. It is slightly larger with a 
molecular weight of about 750 Da and more polar, but kills with a similar, bacteriostatic 
mechanism of action. The experiment was carried out with PAO1, all efflux deficient 
mutants, and their respective pore variants. Since in P. aeruginosa, MexAB-OprM and 
MexXY-OprM are the most clinically relevant transporters, due to their broad 
specificities and high levels of expression, we expect to see a significant contribution of 
efflux in the PAO1 strain (89, 131). All efflux deficient strains are lacking these two 
efflux pumps, leading to significantly reduced efflux capacities even in PΔ3. Hence, 
when comparing the deep efflux deletion strains, we are able to see the contribution of 
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“minor” or “silent” transporters. In addition to the RND transporters and their 
respective MFP, PΔ4 and PΔ6 are also lacking the OMFs. Since these proteins are 
usually promiscuous, the difference between PΔ3 and PΔ4 highlights the contribution of 
all transporters that depend on the outer membrane factors OprM and OprJ as well as 
the transporter MexJK. Furthermore, MexJK has been reported to be at least partially 
reliant on OprM to facilitate efflux (95). Consequently, any changes in antibiotic 
susceptibility between PΔ4 and PΔ6 can be attributed to either the transporters MexEF 
and TriABC, or the outer membrane factor OprN. 
 Looking at the growth inhibition with azithromycin for non-hyperporinated 
strains (Figure 1.10A), we see the contribution of efflux towards resistance to this 
antibiotic. There is a 16-fold difference between in the MIC of azithromycin of PAO1 
and PΔ3, indicating that azithromycin is recognized as a substrate by the major 
transporters. In addition, we measured a two-fold MIC difference between PΔ3 and the 
two deep efflux deficient strains PΔ4 and PΔ6, suggesting that some efflux pumps 
expressed at lower levels contribute to resistance of this macrolide. We also noticed 
reduced optical densities for PAO1 at higher, but not fully inhibiting concentrations of 
azithromycin. Possibly indicating that at these concentrations some transporters may 
already be exhausted in their capacities, allowing for a higher intracellular concentration 
of the drug. The exclusion size for the general porins in P. aeruginosa is estimated to be 
three fold lower than for E. coli, suggesting that overexpression of our mutant pore 
might have a more significant impact on susceptibility (30). Indeed, comparing the MIC 
of PAO1 and PAO1-Pore, we measured a 64-fold difference. This highlights that there 
is significant synergy between the outer membrane barrier and active efflux for 
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azithromycin (Fig. 1.10B and Table 1.2). Surprisingly, the contribution of the pore had 
a similar effect in PAO1 than it had in our efflux deficient strains. Hyperporination 
resulted in a similar 64 to 128-fold decrease in the MIC of all strains. Since the pore 
essentially increases the periplasmic concentration of the drug and the transporters 
translocate substrates from the periplasm, potentiation indicates that the high 
periplasmic concentration saturates the capacities of some transporters resulting in 
inefficient efflux. The fact that we see this potentiation even in the mutants, suggests 
that there is still significant efflux present. The deletion of efflux in conjunction with 
hyperporination shows a staggering 4,000-fold difference on susceptibility. 
Furthermore, the deletion of transporters and the expression of the pore individually 
potentiated the activity of azithromycin, which shows that there is significant synergy of 
the two in the efflux of this compound. Overall, macrolides in P. aeruginosa and E. coli 
showed a synergistic effect of the outer membrane and efflux. 
 Next, we tested the growth inhibiting effects of carbenicillin on the constructed 
P. aeruginosa strains (Fig. 1.10C and D). Carbenicillin is a beta-lactam with a 
molecular weight of about 380 Da and is also highly polar. Beta-lactams are considered 
bactericidal and inhibit transpeptidases that are required for the proper synthesis of 
peptidoglycan. In contrast to the previous antibiotics, the target of carbenicillin is in the 
periplasm, which could significantly affect the susceptibility of our pore strains to the 
drug. Since the mutant pore permeabilizes the outer membrane, the antibiotic would 
have direct access to its target without being limited by slow diffusion through general 
porins. Looking at our results, we measured a 16-fold difference in the MIC between 
the pore strains and their non-hyperporinated counterparts. This suggests that diffusion 
78 
through the pore is still somewhat of a limiting factor and does not give unrestricted 
access to the periplasm. The major efflux transporters of P. aeruginosa also contribute 
to resistance of this antibiotic. We measured a 32-fold decrease in the MIC of 
carbenicillin between PAO1 and PΔ3 (Fig. 1.10C and Table 1.2). We did not measure a 
difference between PΔ3 and PΔ4, and a 2-fold MIC reduction between PΔ4 and PΔ6. 
Surprisingly, when comparing efflux in the pore producing strains, we were still able to 
measure a 32-fold difference between PAO1-Pore and the efflux deficient pore strains 
(Fig. 1.10D and Table 1.2). If diffusion to the periplasm was unrestricted in pore strains, 
active efflux across the outer membrane should only have a minimal impact on 
susceptibility. This highlights that, although the pore drastically increases the outer 
membrane permeability, diffusion through the pore is still a limiting factor. In addition, 
our results also highlight that there is synergy between the outer membrane and efflux 






Figure 1.10 - Growth inhibiting effects of azithromycin and carbenicillin in P. 
aeruginosa. 
Hyperporination in P. aeruginosa affects the activity of the two antibiotics in efflux 
proficient and deficient strains. Growth inhibition of azithromycin (A and B) and 
carbenicillin (C and D) with and without the pore as indicated. Indicated strains were 
induced with 0.1 mM IPTG and grown for 18 hours. After incubation, the optical 








MICs in µg/ml Azithromycin Carbenicillin 
PAO1 64 32 
PΔ3 4 1 
PΔ4 2 1 
PΔ6 2 0.5 
PAO1-Pore 1 2 
PΔ3-Pore 0.031 0.063 
PΔ4-Pore 0.031 0.063 
PΔ6-Pore 0.016 0.063 
Table 1.2 - Minimal inhibitory concentrations (MICs) of azithromycin and 
carbenicillin in hyperporinated or efflux deficient P. aeruginosa strains. 
 
 Overall, the pore increases susceptibilities in P. aeruginosa in much the same 
way it does in E. coli. Differences between the permeabilities of the cell envelopes of 
the two species are readily visible. Smaller antibiotics are not potentiated in E. coli by 
the pore, likely due to the large exclusion size of its general porins. In contrast, the pore 
significantly increases the susceptibilities of small antibiotics in P. aeruginosa, 
presumably because of a lack of general porins with large exclusion sizes in the 
bacterium. However, for large antibiotics that exceed the exclusion size of the porins of 
both organisms, hyperporination has a significant effect on susceptibility in both 
species.  
  
1.3.5 Hyperporination increases the uptake of the fluorescent dye Hoechst 33342.  
 To measure the kinetic uptake of compounds in the pore strains, we decided to 
utilize environment-sensitive fluorescent probes. The approach of using radiolabeled 
antibiotics did not yield high enough resolution to accurately analyze accumulation and 
resulted in significant error in P. aeruginosa, presumably due to the differences of the 
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outer membrane and its tendency to form aggregates. Fluorescent dyes like Nile red, 1-
N-phenylnaphthylamine (NPN), or Hoechst 33342 (HT) have been used in the past to 
assess the activity of efflux transporters and yield better time resolution (132-135). The 
method relies on the fact that the probes shift their emission spectra when they enter a 
hydrophobic environment, like binding the cell membrane or engaging in π-stacking 
interactions with DNA. For this experiment, we grew and washed cells in the same 
manner as for the radioactivity assay and, using a microplate reader with an injector 
system attached, added them to a 96-well plate that contained different concentrations 
of the fluorescent dye. Subsequently the fluorescence emission was read for 10 minutes 
every 20 seconds. The data output resembles that of a signal exponential function, thus 
we decided to fit the uptake kinetics to an equation in the form of: 
    𝐅 = 𝐀𝟏 + 𝐀𝟐 𝟏 − 𝐞+𝐤𝟐∗𝐭     ( 1 ) 
Thus, the rate of uptake is given by: 
    𝐅 = 𝐀𝟏 + 𝐀𝟐 − 𝐀𝟐𝐞+𝐤𝟐∗𝐭    ( 2 ) 
 
    𝐝𝐅
𝐝𝐭
= 𝐀𝟐 ∗ 𝐤𝟐𝐞+𝐤𝟐∗𝐭     ( 3 ) 
Since at the initial rate of uptake t = 0, the rate can be described as: 
    𝐢𝐧𝐢𝐭𝐢𝐚𝐥	𝐫𝐚𝐭𝐞 = 𝐀𝟐 ∗ 𝐤𝟐    ( 4 ) 
 
In addition, the amplitudes A1 and A2 can provide information about the total 
accumulation of fluorophore inside the cell.  
 Here we measured the uptake of Hoechst 33342 into E. coli and P. aeruginosa 
strains. Hoechst 33342 (HT) (Fig. 1.14D) is about 450 Da in size and is frequently used 
to stain DNA. It has an affinity to hydrophobic environments and binds to DNA as well 
as lipids. To relate the fluorescent units of the experiment to actual concentrations, we 
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measured binding of increasing concentrations of HT to either DNA or lipids alone. The 
calibrations were done assuming that 1 ml of cells at OD600 of 1.0 contain 17 µg of 
DNA and 27 µg of lipids (136, 137). We incubated HT with either DNA or lipids and 
measured the emission at 450 nm (excitation at 350 nm). The linear dependence of the 
fluorescent signal to the concentration of HT allowed us to calculate the emission 
coefficient of HT bound to either lipids or DNA.  
 When HT is incubated with cells, there is a very fast initial increase in the 
fluorescent signal (Fit. 1.11). For the purpose of our analysis, this was attributed to HT 
binding to lipids which are readily available on the outer membrane. In our fitting 
routine, this fast step is characterized by the first amplitude A1 (Fig. 1.12B). 
Unfortunately, this step happens too fast for our equipment to measure the 
corresponding rate, since we are unable to accurately determine the exponent k1. 
Following this fast step is a slower increase in fluorescence, which is interpreted as HT 
diffusing into the cell and binding to intracellular DNA. Consequently, the amplitude A1 
is converted to concentration using the lipid emission coefficient and A2 using the DNA 
emission coefficient. Thus, the sum of both amplitudes describes the total accumulation 
of HT in the cell.  
 To fit large sets of uptake data to the equation above, scripts were written in 
Matlab (MathWorks) utilizing the fittype function in loops. This provided a fast way to 
extract the parameters A1, A2, and k2 from uptake experiments with a wide range of 
fluorophore concentrations. Before fitting was performed, the datasets were inspected 
for outliers and the fluorescence signal was normalized to the initial emission of the 
fluorophore. Once the fitted parameters were determined, the initial rates and steady 
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states of fluorophore accumulation were calculated. The reported values are an average 
of at least three experiments. The uptake experiments reported here were carried out by 
Dr. Ganesh Krishnamoorthy, while this author was responsible for the data analysis. 
The E. coli results were further applied to a novel kinetic model of drug accumulation 
inside bacterial cells developed by Dr. Valentin Rybenkov and David Westfall (138). 
The P. aeruginosa data has been submitted as part of a separate manuscript. 
 For the HT uptake in E. coli, we found that the results are similar to what we 
previously measured with the radiolabeled [14C]-erythromycin, albeit with much better 
resolution. Looking at the time courses of HT uptake (Fig. 1.11), WT had the overall 
lowest fluorescent signal. When comparing the WT to ΔTolC, we notice a similar first 
initial increase in fluorescence but the subsequent uptake in the efflux deficient strain is 
much higher. This is reflected in the initial rates (Fig. 1.12A) and values of A1 (Fig. 
1.12B) plotted against the extracellular HT concentration. The parameter A1 represents 
the amount of HT that initially binds to freely accessible lipids, which should be 
comparable between the WT and ΔTolC strains. At higher concentrations, the graph of 
both strains reaches a plateau, which is likely due to saturation of the available binding 
sites of the membrane. Looking at the initial rates of HT uptake for WT and ΔTolC 
(Fig. 1.12A), we see a similar sigmoidal curve for both strains. Here, a sigmoidal trend 
suggests that transporters initially limit the rate of uptake. Once the concentration of HT 
is increased to levels significantly above the Km of a given transporter, its efflux 
capacity is exhausted and it can no longer efficiently reduce the uptake(138). Thus, the 
initial rate of uptake increases faster. Increasing the concentrations further results in a 
plateau, suggesting that the initial rate reaches a maximum and that higher 
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concentrations of the fluorophore won’t increase this rate any more. Active efflux 
provided by TolC dependent transporters significantly lower the rates of uptake at all 
concentrations tested, suggesting that we are not exceeding the Km for at least some of 
the transporters. The fact that we still see sigmoidal behavior in ΔTolC highlights that 
this strain is not completely deficient in efflux. When comparing the WT to WT-Pore, 
we saw a similarly small rate of uptake at very low extracellular concentrations of HT. 
However, the pore significantly increases the uptake at higher concentrations. At very 
high concentrations, the rate of uptake of the WT-Pore strain is similar to ΔTolC-Pore, 
suggesting that TolC dependent transporters are overwhelmed and can no longer 
provide efficient efflux. We noticed a similar trend for the initial binding of lipid in the 
pore strains. This binding is increased in strains expressing our mutant pore, which 
suggests that the pore initially provides more access to membrane binding sites. This 
could likely include binding to the inner membrane and explain the differences in the 
sigmoidal shapes of the WT-Pore and the ΔTolC-Pore strains. TolC dependent 
transporters can capture the dye from the inner membrane and expel them from the cell, 
which could explain the lower initial concentration of HT. The fact that ΔTolC-Pore 
still exhibits sigmoidal behavior suggests that it still has significant efflux, suggesting 
that other non-TolC dependent transporters exist and are able to utilize HT as a 
substrate. Unfortunately, we are unable to reliably estimate the second amplitude A2, 
because the time courses of the uptake experiments did not saturate for all 
concentrations. Thus, we are unable to estimate the total steady state accumulation of 




Figure 1.11 - Time courses of HT uptake in E. coli strains. 
HT uptake in WT (A), WT-Pore (B), ΔTolC (C), and ΔTolC-Pore (D) at increasing 
concentrations of HT (0.5-16 µM). Data was fit to an exponential equation and initial 
rates and accumulation of HT was calculated. Lines in red indicate fitted lines. Error 








Figure 1.12 - Fitted parameters and growth inhibition of HT. 
A: Initial rates of HT uptake in all four E. coli strains. B: Initial binding of HT to lipids, 
as indicated by the first amplitude. C: Inhibition curves of HT. Error bars are SD (n=2 












 Since HT binds to DNA, it is toxic to the cell and exhibits antimicrobial 
behavior. To test whether the uptake correlates with MICs for HT, we measured the 
susceptibility of our strains to the dye (Fig. 1.12C). Surprisingly, although the pore 
increased the rate of HT uptake significantly, it almost has no effect on the MIC of the 
fluorophore. We only measured a two-fold reduction of the MIC when the pore is 
expressed. In contrast, efflux had a significant impact on the MIC, resulting in a 32-fold 
difference between WT and ΔTolC. This result shows that our results from the uptake 
experiment do not correlate with the measured MICs and the fluorescent signal is not 
directly related to binding of HT to its target. 
 When looking at the time courses of uptake in P. aeruginosa, we notice some 
similarities with E. coli (Fig. 1.13 and Fig. 1.14). In both bacteria, the pore significantly 
increases the accumulation of HT inside the cell. When comparing the steady state 
accumulation between the strains expressing the pore and not expressing the pore (Fig. 
1.15B and C), we see that the overall uptake of HT is higher in pore strains. This is 
especially true at higher extracellular HT concentrations, where efflux capacities are 
exhausted. Looking at the overall uptake in non-pore expressing strains (Fig. 1.15B), we 
noticed a big difference between PAO1/PΔ3 and PΔ4/PΔ6. This could either point 
towards minor, lower expressed transporters having a bigger effect of uptake of HT or, 
more likely, that the absence of OMFs in PΔ4 and PΔ6 decreases efflux. OMFs in P. 
aeruginosa are promiscuous and can be used by several transporters, thus deleting them 
might also inactivate other efflux pumps (94). Surprisingly, the overall lowest 
accumulation of HT was measured in PΔ3 and not PAO1.  
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 Looking at the uptake in hyperporinated strains (Fig. 1.14C), the contribution of 
the major efflux transporters on accumulation of HT is readily visible. In contrast to the 
non-pore strains, PAO1-Pore showed the lowest total uptake at all concentrations tested. 
Furthermore, we can clearly see that increasing the extracellular concentration of HT 
beyond 6 µM overwhelms the major transporters in P. aeruginosa, allowing for higher 
levels of accumulation. This sigmoidal behavior can also be seen in PΔ3. However, the 
transporters already saturate at about 3 µM, highlighting the difference in efflux 
capacities between the two strains. The difference between PΔ3-Pore and the deeper 
efflux deletion mutants suggests a contribution of minor transporters on HT uptake.  
 When looking at the initial rates (Fig. 1.14A), we also noticed that the pore 
significantly increases the rates of HT uptake. Surprisingly, PAO1 showed a higher rate 




Figure 1.13 - HT uptake in PAO1 and PΔ3. 
Time courses of uptake in the indicated P. aeruginosa strains with and without the pore. 
HT concentrations used were from 0.5 to 16 µM. Lines in red indicated fitted lines. 





Figure 1.14 - HT uptake in PΔ4 and PΔ6. 
Time courses of uptake in the indicated P. aeruginosa strains with and without the pore. 
HT concentrations used were from 0.5 to 16 µM. Lines in red indicated fitted lines. 





Figure 1.15 - Fitted parameters of HT uptake in P. aeruginosa. 
A: Initial rates of uptake of all P. aeruginosa strains. B and C: Total accumulation of 
HT in P. aeruginosa strains with (C) and without (B) the pore. D) Structure of Hoechst 












PAO1 64 64 
PΔ3 16 2 
PΔ4 4 1 
PΔ6 2 0.5 
Table 1.3 - Susceptibilities of P. aeruginosa strains to HT. 
 
 Like in E. coli, the MICs of HT do not always correlate with the overall 
accumulation of the fluorophore (Fig. 1.15D). For example, the measured MIC in PAO1 
was 64 µg/ml with and without the pore. This suggests that the major transporters can 
compensate for the increase in outer membrane permeability. However, the pore clearly 
increased the overall accumulation of HT. Furthermore, PΔ3 showed a lower uptake 
than PAO1 but its MIC is below that of PAO1 by 4-fold. Again, this suggests that HT 
might have a different target inside the cell. However, the rest of the MICs generally 
agree with the trends we see in the uptake experiments. The pore decreases the MICs of 
all the efflux deficient strains by 4 to 8-fold, and it also increases the overall HT 
accumulation in those strains. In addition, there is also a 4 to 8-fold difference between 
PΔ3 and PΔ4/PΔ6, suggesting a contribution of minor transporters in resistance. This is 
also in agreement with our uptake experiments, which show higher accumulation of HT 
in the deeper efflux deficient strains. 
 
1.4 Discussion 
 Infections caused by multidrug resistant bacteria are becoming increasingly 
more difficult to treat, which could lead to a time when conventional antibacterial 
therapy will be insufficient to cure these diseases. This has never been as true as it is 
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now with the discovery of resistance to last line of defense antibiotics, like the recent 
finding of colistin resistance in a US hospital (2). Gram-negative bacteria pose a unique 
challenge in the fight against drug resistance due to the synergy of active efflux and low 
outer membrane permeability (5). Slow diffusion across the outer membrane limits the 
concentrations of antibiotics in the periplasm, so that the substrate concentrations of 
efflux transporters are kept low. This allows them to operate efficiently, providing 
robust intrinsic resistance. The study of this synergism requires a detailed analysis of 
the individual contributions of efflux and the outer membrane barrier.  
 RND transporters have been studied extensively and their activity can readily be 
determined by simple chromosomal deletions and the measurement of drug 
susceptibilities. On the contrary, removal of the contribution of the outer membrane 
barrier on drug resistance has been extremely difficult. Current methods to permeabilize 
the outer membrane, like the use of polymyxins, significantly change the properties of 
the outer membrane and disproportionately favor the uptake of hydrophobic compounds 
(102, 103). This makes them inadequate for the study of the outer membrane 
permeability barrier. 
 In this study, we introduce a novel approach at permeabilizing the outer 
membrane without changing its physical properties by the expression of a genetically 
engineered pore protein. This approach does not affect cell viability (Fig. 1.6F) and 
increases the uptake of compounds inside the cell (Fig. 1.9, 1.12, and 1.15). 
Furthermore, the pore sensitizes cells to large antibiotics that are generally thought to be 
unable to cross the outer membrane (Fig. 1.3). 
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 Controlling the outer membrane permeability has significant advantages for the 
development of new antibiotics. Gram-negative bacteria are notorious for their low hit 
rate during drug screening (7), which limits the amount of possible lead compounds. 
Utilizing this hyperporination approach during the screening process would 
significantly increase the number of hits resulting in an increase in the number of lead 
compounds and the discovery of new antibiotics. Furthermore, structural properties that 
allow antibiotics to penetrate the cell envelope are largely unknown. Some antibiotics, 
like the aminoglycosides, are able to promote their own uptake by a mechanism that is 
proposed to be similar to that of polymyxins (139). However, it is still difficult to 
predict the penetration of other compounds through the outer membrane barrier. The 
potentiation of a compound by hyperporination reveals the contribution of the low 
permeability outer membrane and whether diffusion through it limits its activity. This 
could potentially lead to the discovery of the so called “rules of permeation”, an as of 
yet unknown list of structural characteristics that facilitate faster diffusion through the 
barrier. Overall, hyperporination has significant implications for the development of 








Chapter 2.  Differential contribution of active efflux and the outer membrane 
barrier on drug susceptibility 
2.1 Abstract 
 The increased frequency of multidrug resistant isolates of infectious 
pathogens necessitates improvements to the way we discover antibiotics. Current 
efforts in the field have only produced one novel class of antibiotics in the last 50 
years (140). One of the major bottlenecks is the screening process in gram-negative 
bacteria due to their high levels of intrinsic resistance provided by a low 
permeability outer membrane and active efflux (5). Here, we are utilizing a 
combination of efflux deficient and hyperporinated strains to study the differential 
contribution of active efflux and outer membrane permeability on antimicrobial 
susceptibility. Our results suggest that most antibiotics belong to one of four 
groups depending on their potentiation by the deletion of efflux or 
hyperporination. This study also highlights the differences of the cell envelope of P. 
aeruginosa and E. coli and that so-called “rules of permeation” will likely be 










 Infections caused by multidrug resistant bacteria are becoming increasingly 
more frequent and are projected to even surpass cancer as one of the leading causes of 
death (1). As seen in a recent report by the US Center for Disease Control, the most 
critical threats are drug resistant gram-negative bacteria (6). Gram-negative bacteria 
possess a high level of intrinsic resistance due to their low permeability outer membrane 
and an arsenal of efflux pumps that significantly decrease the intracellular accumulation 
of antibiotics. The low outer membrane permeability coupled with active efflux causes 
problems not only in the treatment of patients with infections, but also in the process of 
drug discovery. The hit rate during drug screening is estimated to be 1,000-fold lower 
for P. aeruginosa when compared to gram-positive bacteria and is one of the major 
bottlenecks in the discovery of new antibiotics against gram-negatives (7). Improving 
the antibiotic pipeline is of great importance to ensure the continued efficacy of our 
arsenal of drugs. Currently, the frequency of emergence of drug resistance is much 
higher than the amount of time it takes to discover and approve new antibiotics. This 
will ultimately result in a post-antibiotic era where some infections can no longer be 
efficiently treated (141). Hence, new innovations in the drug discovery pipeline are 
desperately needed. 
 To study the permeability of the gram-negative cell envelope, it is necessary to 
separate the contributions of the outer membrane and active efflux on drug activity. It is 
important to identify which chemical features allow antibiotics to easily diffuse through 
the outer membrane or to circumvent efflux. Here, we are describing the use of efflux 
proficient and deficient E. coli and P. aeruginosa strains that have a chromosomally 
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encoded open pore in order to study the contribution of active efflux and outer 
membrane permeability on drug activity. The pore is a genetically modified porin from 
E. coli that was altered by removing 4 extracellular loops and its cork domain, resulting 
in an internal diameter of about 2.4 nm that can facilitate diffusion of large molecules 
(106, 122, 123). Expression of the pore is inducer-dependent and does not result in 
significant changes to the physiology of the bacteria (106). Furthermore, uptake 
experiments utilizing radiolabeled [14C]-erythromycin showed that the pore increases 
the accumulation of this large antibiotics (106).  
 Using these strains, we tested the contributions of the outer membrane and 
active efflux to resistance of a range of antimicrobials belonging to different classes of 
drugs. Our findings suggest that antibiotics can be clustered into four distinct groups, 
which are divided based on their potentiation by hyperporination, deletion of efflux, or 
both. Furthermore, these groups differ between E. coli and P. aeruginosa due to 
differences in their respective outer membrane permeability and arsenal of RND 
transporters. Grouping antibiotics this way may lead to the discovery of specific 
chemical features that facilitate uptake into the cell. In addition, our studies showed that 
measuring MICs in hyperporinated strains reveals true substrate specificities of efflux 
transporters and that the outer membrane barrier can significantly mask the 
contributions of these pumps. We present here a first approach to separate the 
synergistic effects of the outer membrane from active efflux on antimicrobial activity in 
gram-negative bacteria. The antimicrobial susceptibility tests described here were 




2.3.1 Interpretation of antimicrobial susceptibilities in the context of 
hyperporination. 
 Measuring antimicrobial susceptibility is typically done by MIC experiments. 
The minimal inhibitory concentration (MIC) is the concentration of a compound that 
inhibits visible growth of the bacteria. The traditional way of determining the MIC is by 
two-fold broth dilution in a 96-well plate of the compound and subsequent inoculation 
of the bacteria into each well. The plates are incubated at 37°C for 16-20 hours 
depending on the organism and the MIC is determined visually (113). The MIC does 
not give any indication of whether the compound is bactericidal or bacteriostatic and 
cannot be used to determine the activity of the compound in vivo, as there are many 
pharmacokinetic and pharmacodynamic parameters that need to be considered (113). 
Hyperporination of some antibiotics has a significant impact on the MIC and 
interpretation of such results needs to be evaluated with the context of permeability and 
active efflux due to the existence of synergy between the two. The following 
interpretations are made based on our novel kinetic model of drug uptake which was 
submitted and is currently under review(138). 
 In order for cell growth to be inhibited by a compound, it needs to accumulate to 
a certain concentration threshold inside the bacteria to efficiently bind its target. This 
intracellular concentration threshold is largely determined by the KD of the compound 
and its target. Consequently, the MIC is determined by the extracellular concentration 
of the drug that allows the compound to sufficiently accumulate inside the cell past this 
threshold. Accumulation is largely hindered by diffusion across the outer membrane and 
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the opposing flux of efflux transporters. These two forces act in synergy, meaning that 
the low outer membrane permeability significantly limits the flux across the membrane 
barrier. Thus, the effective periplasmic concentrations of the antimicrobial that RND 
transporters encounter at any given time is much lower than what is present outside the 
cell. As we will see in the results, this lower periplasmic concentration allows 
transporters to provide effective efflux. This synergy provides effective means to 
protect the cell from the compound. However, since we are able to measure MICs for 
the vast majority of the antimicrobials, increasing the extracellular concentrations of the 
drug eventually leads to higher periplasmic accumulation due to higher rates of passive 
diffusion across the barrier. If the drug concentration in the periplasm is higher than the 
Km of the transporter and its activity approaches Vmax, the transporter is overwhelmed 
and efflux is inefficient. At that point, increasing the extracellular concentration of the 







Figure 2.1 - Correlation between drug accumulation and active efflux in the 
context of hyperporination. 
Simplified model of the accumulation of antimicrobials and its dependence on the 
synergy between the outer membrane and active efflux. The dotted, red line signifies 
the intracellular concentration threshold required for inhibition of bacterial growth. The 
y- and the x-axis show the intracellular and extracellular drug accumulation 
respectively. A: Theoretical accumulation of efflux proficient (WT), ΔEfflux, and WT-
Pore cells. Accumulation in ΔEfflux cells is largely determined by passive diffusion. 
The WT curve shows slow initial uptake due to efficient efflux. Once the periplasmic 
concentration is high enough, the transporter is overwhelmed and drug accumulation 
increases. Hyperporination of the WT (WT-Pore) allows for increased flux across the 
outer membrane, resulting in a higher periplasmic concentration of the drug. The 
transporters are overwhelmed at a lower extracellular concentration. B: This figure is in 
agreement with most of our fluorescent uptake studies. The ΔEfflux mutant is not 
completely efflux deficient and hyperporination still potentiates compounds in this 
strain. C: If binding sites on the outer membrane are saturated before the drug can 
overwhelm efflux, the intracellular concentration of the compound will plateau and 
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never reach the concentration threshold required to inhibit the growth of the bacterium. 




 When the cells are hyperporinated, the flux of compounds increases across the 
outer membrane barrier and, consequently, their concentration in the periplasm. Thus, 
lower extracellular concentrations are sufficient to saturate and overwhelm the 
transporter, resulting in a decrease of the MIC (Fig. 2.1A). To further complicate this, 
there are several efflux transporters, each with their own Km, that transport their 
substrates across the inner and outer membrane. In E. coli, most efflux across the outer 
membrane is depleted by deleting the universal OMF TolC (55). Hence any observed 
efflux in the ΔTolC mutant is likely due to transporters that translocate their substrates 
across the inner membrane. P. aeruginosa has several RND transporters encoded on its 
chromosome, many of which with their own OMF, which makes it significantly more 
difficult to deplete efflux across the outer membrane alone. The transporters also differ 
in their substrate specificities. If more than one transporter is contributing to efflux of a 
compound, increasing the extracellular concentration should overwhelm the transporters 
sequentially according to their respective Km of the substrate. Furthermore, our 
observations from kinetic uptake experiments utilizing fluorescent dyes showed that our 
efflux deficient mutants still possess efflux capacities. We detected a low initial 
accumulation that, after a certain extracellular concentration (about 3 µM of HT in P. 
aeruginosa), became more rapid. Thus, our results most closely resemble a drug 
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accumulation model that can be seen in figure 2.1B, which shows the presence of efflux 
in all four strains. Another possibility is that the drug will saturate the available binding 
sites on the outer membrane before it can accumulate to high enough levels to 
overwhelm the efflux transporter. In this case, efflux will always operate efficiently and 
render the cell completely resistant (Fig. 2.1C). Due to the limited nature of MIC 
measurements, we will not be able to determine whether there is still residual efflux in 
our efflux deficient and hyperporinated strains. However, we will be able to delineate 
the contributions of the outer membrane and active efflux at growth inhibiting, 
intracellular concentrations.  
 
2.3.2 Effects of efflux and outer membrane permeability on drug susceptibilities of 
E. coli. 
 We tested the antimicrobial susceptibilities of BW25113 (WT), BW25113 with 
insertion of fhuAΔC/Δ4L (WT-Pore), the BW25113 TolC mutant GD102 (ΔTolC), and 
GD102 with fhuAΔC/Δ4L (ΔTolC-Pore) using antibiotics from a wide range of classes. 
To rule out a negative impact of the arabinose promoter of the fitness of the pore 
strains, we inserted this promoter together with the multiple-cloning site of the plasmid 
pTJ1 into our non-pore expressing variants. Expression of the pore was induced with 
0.1% arabinose, which we previously showed to results in about 150 copies of the pore 
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Table 2.1 - Antibiotic susceptibilities of E. coli strains to different classes of 
antibiotics. 
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 The susceptibilities were determined by MIC measurements using the traditional 
two-fold broth dilution method into 96-well plates. Cultures were first grown to OD600 
of 0.3, induced, and further grown to an OD600 of 1.0. Cells were inoculated into the 
plates at an inoculum size of 5*105, as is commonly done (113), and incubated for 16 
hours at 37°C. Arabinose was present in all wells throughout the incubation time to 
ensure proper expression of the pore. The MIC was determined visually or, 
alternatively, the absorbance at OD600 was read using a micro-plate reader. 
Contributions of active efflux and outer membrane permeability were determined by 
calculating the fold change of the MIC due to the loss of efflux or the introduction of 
the mutant pore. The results can be seen in table 2.1. 
 Based on our results, we can divide the antibiotics into four groups depending 
on their potentiation by efflux, hyperporination, or both. Group I antibiotics are neither 
affected by hyperporination, nor by deletion of efflux, and are exclusively made up of 
aminoglycosides. Aminoglycosides bind the 30S subunit of the ribosome and inhibit 
protein synthesis, and need to permeate both membranes to reach their target. These 
antibiotics are highly polar as seen by their very low logD values compared to all other 
antibiotics tested (Fig. 2.2). The logD is a measure of polarity and is calculated by the 
decadic logarithm of the concentrations of ionic and non-ionic species of a compound in 
octanol divided by their concentrations in water. Hence, a low logD means that the 
particular compound mainly partitions into the aqueous phase. Aminoglycosides 
typically contain several amino groups that carry a positive charge at physiological pH 
and are thought to permeate the cell envelope by a “self-promoted” uptake mechanism 
(139). The positively charged aminoglycosides displace divalent ions at the outer leaflet 
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of the outer membrane and disrupt the organization of lipopolysaccharides (LPS) (139). 
This causes the membrane to permeabilize and allows for increased uptake of the drug. 
We noticed no significant potentiation of the activity of the aminoglycosides when we 
expressed the pore, which suggests that this “self-promoted” uptake is not a limiting 
factor for these drugs to enter the cell. Additionally, there is no significant difference 
between WT and our TolC deletion mutant, suggesting that there are no aminoglycoside 
proficient transporters that translocate substrates across the outer membrane in E. coli.  
 The second group consists of antibiotics that are affected by hyperporination but 
not efflux. Most members of this group are large antibiotics like coumermycin and 
rifampin (Table 2.1 and Fig 2.2). Their size is well above the cut off of the major porins 
in E. coli OmpF/C, and hyperporination allows them access to the cell. Efflux 
transporters are not proficient in transporting these compounds, likely because they 
cannot penetrate the cell envelope and transporters have not evolved to use them as 
substrates. Interestingly, β-lactams are also part of this group and are somewhat of an 
exception. These antibiotics are below the exclusion size of the general porins and were 
shown to diffuse through OmpF (142). However, the fact that hyperporination 
potentiates the activity of this class of antibiotics suggests that this diffusion is still a 
limiting factor for these antimicrobials. β-lactams target the cell wall synthesis in the 
periplasm and their accumulation in hyperporinated strains is likely greatly increased. 
Efflux also somewhat effects their activity, however the outer membrane permeability 
seems to be the major determinant of their MIC. 
 The third group is the largest one of the drugs tested, and is potentiated by 
deletion of efflux but not by hyperporination. This group consists of chloramphenicol, 
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tetracycline, proflavine, triclosan, and fluoroquinolones. With the exception of triclosan 
and tetracycline, their logD values are around zero, suggesting that they are amphiphilic 
in nature (Fig. 2.2). Furthermore, they are all below the exclusion size of OmpF/C. 
Thus, these antibiotics likely freely diffuse either through general porins or the outer 
membrane. Our data suggests that this diffusion is fast, since hyperporination has no 
impact on these antibiotics. Deletion of TolC dependent efflux results in a modest 4 to 
8-fold change of the MIC on average.  The exception to this is novobiocin, which 
showed a staggering 256-fold change in susceptibility with the deletion of TolC. 
Novobiocin is an aminocoumarin and targets DNA gyrase. Interestingly, the other 
aminocoumarin tested, coumermycin, is a group II antibiotic and, thus, only affected by 
hyperporination and not efflux. The molecular weight of novobiocin is significantly 
lower than coumermycin, allowing it to permeate the cell envelope through general 
porins. This is, presumably, why efflux transporters are proficient in the efflux of 










Figure 2.2 - Features of antibiotics divided into four groups in E. coli. 
A: Correlation between logD and the respective molecular weight of antibiotics 
belonging to the four groups. Outliers are marked by a square shape with their 
corresponding name. B: Average MIC fold changes of the indicated strains of 












 Group IV antibiotics are potentiated by hyperporination and efflux. For these 
antibiotics, efflux acts in synergy with the outer membrane to significantly limit their 
accumulation inside the cell. Members of this group include macrolides, as well as the 
smaller antibiotics virginiamycin and the β-lactam cloxacillin. Macrolides are large 
antibiotics that cannot freely diffuse through general porins. However, other than group 
II antibiotics, efflux transporters are able to use them as substrates. Surprisingly, 
hyperporination of the TolC deficient strain further decreased their MIC, suggesting that 
there is significant efflux across the inner membrane of these antibiotics. Interestingly, 
cloxacillin, a member of the β-lactam family, is also part of this group. Other than 
ampicillin and carbenicillin, this β-lactam is a very good substrate of efflux pumps, as 
seen by a 512-fold decrease of the MIC once TolC is deleted. Since its target is in the 
periplasm, cloxacillin is not potentiated by hyperporination in the ΔTolC strain. The 
detergent SDS is also in this group also falls into this group and its activity is 
significantly affected by outer membrane permeability and efflux. Similar to cloxacillin, 
SDS is not affected by the mutant pore in the ΔTolC strain, suggesting that it is not a 
substrate of transporters that translocate substrates across the inner membrane. 
Surprisingly, there is a significant difference when comparing the contribution of efflux 
in cells with an intact outer membrane and hyperporinated cells. In cells without the 
pore, this contribution varies from 32 to 512-fold, but in cells expressing the mutant 
pore the fold change is much lower and constant between 16 and 32-fold. This 
highlights that the outer membrane barrier masks substrate specificities and efflux 
capacities of transporters, and removal of this barrier reveals the actual contribution of 
efflux on the activity of antimicrobials. 
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2.3.3 Antibiotic susceptibilities in hyperporinated and efflux deficient P. 
aeruginosa variants. 
 Next, we tested a similar range of antibiotics on drug susceptibility in the P. 
aeruginosa strains described in chapter 1 with the exception of PΔ3, which was 
replaced with a close relative PΔ3S (ΔmexAB-oprM ΔmexCD-oprJ ΔmexJKL) and its 
pore expressing variant. Similar to PΔ3, this strain is deficient in three efflux 
transporters. We chose this strain because it lacks the OMFs OprM and OprJ, making it 
more similar to PΔ4 and PΔ6. This should allow for a better comparison of the 
contributions of minor efflux transporters. Insertion of the pore in this strain was 
confirmed by PCR and functionality tested via vancomycin spot assays. The cell 
envelope of P. aeruginosa is significantly different from E. coli and its permeability is 
reduced largely due to the absence of general porins with large exclusion sizes (5, 30, 
32). Thus, we are expecting differences in the potentiation of MICs by hyperporination 
compared to E. coli. Additionally, P. aeruginosa has a much larger arsenal of RND 
transporters, making it significantly more difficult to reduce the efflux across the outer 
membrane. Any differences we see in efflux deficient strains when we introduce the 
mutant pore are likely due to contributions of minor transporters. The results of the 










































































































































































































































































































































































































Table 2.2 - Susceptibilities of P. aeruginosa strains to different antibiotics. 
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 Again, we divided the antibiotics up into four groups by whether they are 
potentiated by hyperporination, deletion of efflux, or both. Similar to E. coli, 
aminoglycosides represent group I, due to their “self-promoted” uptake mechanism and 
their ability to circumvent efflux. MexXY-OprM is the only transporter that was 
reported to provide resistance to aminoglycosides, however we do not see potentiation 
of these antibiotics in the OprM deficient PΔ3S or in the MexXY deletion mutants PΔ4 
and PΔ6 (143, 144). Like for E. coli, the “self-promoted” uptake mechanism seems to 
be faster than diffusion through the large mutant pore, hence hyperporination has no 
effect on the activity of these antibiotics. This group of antibiotics is highly effective at 
crossing the gram-negative cell envelope and bypassing the intrinsic resistance 
mechanisms. Aminoglycoside resistance is mainly mediated by aminoglycoside-
modifying enzymes that typically act by transferring acetyl groups onto the antibiotic 
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Table 2.3 - Contributions of efflux and outer membrane permeability to the MIC 
of selected antibiotics in P. aeruginosa. 
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 Group II antibiotics are all fairly large molecules with molecular weights 
exceeding 800 Da. These antibiotics are unable to cross the outer membrane, which 
limits their activity in gram-negative bacteria. Similar to E. coli, efflux transporters are 
unable to use them as substrates, possibly due to the fact that efflux transporters have 
not evolved to translocate these large compounds. The only exception to this may be 
coumermycin, which shows a 4-fold decrease in the MIC when comparing PAO1-Pore 
and PΔ6-Pore (Table 2.3). This change in the MIC is not seen with an intact outer 
membrane, suggesting that the major limiting factor is still the uptake of this antibiotic. 
Structurally, it is very similar to novobiocin, which is an excellent substrate for efflux 
transporters. This could explain why some transporters might be able to translocate 
coumermycin. 
 Group III antibiotics are potentiated by efflux are significantly potentiated by 
the depletion of efflux, but less by hyperporination. These antibiotics are relatively 
small with 200-400 Da (Table 2.3 and Fig. 2.3). Their size should preclude them from 
free diffusion through porins in P. aeruginosa due to their estimated exclusion size of 
200 Da, thus it is likely that they diffuse through the outer membrane (32). 
Alternatively, a small fraction of OprF porins are suggested to form larger channels that 
could facilitate the diffusion of group III antibiotics (146). The group consists of 
fluoroquinolones, chloramphenicols, SDS, and triclosan and generally have a logD 
value of around zero. Two group III members from E. coli are absent in the group III of 
P. aeruginosa. Tetracycline and novobiocin are both group III antibiotics for E. coli. 
They are between 450 and 600 Da which allows them to diffuse through OmpF in E. 
coli, but are too large for diffusion through P. aeruginosa porins. 
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 Group IV consists of antibiotics that are potentiated by depletion of efflux and 
permeabilization of the outer membrane. In contrast to E. coli, this is the largest group 
of the antibiotics tested and also includes the β-lactams ampicillin and carbenicillin, 
both of which belong to group II in E. coli. These two drugs are good substrates of P. 
aeruginosa efflux transporters, but not for TolC dependent transporters in E. coli. In 
addition to β-lactams, macrolides, novobiocin, and tetracycline belong to group IV in P. 
aeruginosa. They appear to have logD values that are further away from zero when 
compared to group III, making them less amphiphilic, and their molecular mass is 










Figure 2.3 - Properties of antibiotics belonging to the four groups in P. aeruginosa. 
A: Correlation between LogD at pH 7.4 and molecular weight for the four groups in P. 
aeruginosa. B: Average MIC fold changes of deletion of efflux or hyperporination. The 












 In P. aeruginosa, we still measured significant contributions of efflux in the 
hyperporinated strains as seen by a 4 to 8-fold greater change in the MIC for triclosan, 
SDS, novobiocin, azithromycin, and cloxacillin due to removal of efflux. This is in 
contrast to E. coli, where the contribution of efflux is either equal to or lower in 
hyperporinated strains. This suggests that efflux still significantly contributes to 
resistance in P. aeruginosa even when the outer membrane permeability is increased. 
Furthermore, the lower fold changes for cells with an intact outer membrane highlight 
that the residual efflux works in synergy with the outer membrane. When looking at the 
contributions of minor efflux transporters on the activity of the tested antibiotics, we 
noticed that for many cases, like ciprofloxacin, azithromycin, erythromycin, and 
tetracycline the stepwise deletion of transporters also resulted in a stepwise reduction of 
the MIC (Table 2.4). The difference between PΔ3S and PΔ4 is the presence of MexXY 
in PΔ3S. This transporter is a major contributor for clinical resistance in P. aeruginosa 
isolates and has a broad substrate specificity (89). This results in a relatively large MIC 
fold change between PΔ3S and PΔ4 for vancomycin (Table 2.4). MexXY is generally 
thought to utilize the outer membrane factor OprM, which is absent in PΔ3S (144). 
However, some research groups reported that it can utilize other outer membrane 
factors like OpmH that are present in PΔ3S (147).  In hyperporinated cells, we did not 
observe this large fold change, suggesting that MexXY is overwhelmed in PΔ3S due to 
high concentrations of substrates in the periplasm and provides inefficient efflux. 
Another large increase in susceptibility is seen for SDS of 16-fold when comparing PΔ4 
and PΔ6. This is likely due to deletion of TriABC, which was previously reported to 
provide resistance to the detergent (148, 149). 
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 MIC fold chages 
 
 PΔ3/ PΔ4/ PΔ3-Pore/ PΔ4-Pore/ 
 Drug PΔ4 PΔ6 PΔ4-Pore PΔ6-Pore   
Amikacin 0.5 1 1 0.5 
Group I 
Tobramycin 1 1 1 1 
Coumermycin 1 1 2 0.5 
Group II Rifampin 1 1 1 1 
Vancomycin 8 0.5 1 2 
Levofloxacin 4 1 1 2 
Group III 
Ciprofloxacin 4 2 2 2 
Nalidixic acid 2 1 1 1 
Chloramphenicol 2 1 2 2 
Triclosan 2 2 4 1 
SDS 1 16 1 2 
Novobiocin 4 1 1 2 
Group IV 
Azithromycin 4 1 2 2 
Erythromycin 2 1 4 2 
Tetracycline 2 2 1 2 
Ampicillin 1 2 4 2 
Cloxacillin 1 1 1 2 
Carbenicillin 2 0.5 2 1 
 










 Overall, the four groups remained largely the same for P. aeruginosa and E. 
coli. The antibiotics that behaved different were β-lactams, which were good substrates 
of transporters in P. aeruginosa but not E. coli, novobiocin, and tetracycline. The last 
two were likely too large to free diffuse through the general porins in P. aeruginosa and 
were significantly potentiated by the expression of the pore. Efflux capacities also seem 
to be higher in P. aeruginosa, likely due to its bigger arsenal of RND transporters. 
Interestingly, P. aeruginosa is more resistant to many antibiotics, like macrolides and 
fluoroquinolones, but when efflux is deleted and the outer membrane permeability is 
increased it is oftentimes more susceptible than E. coli ΔTolC-Pore. This shows that 
overall intrinsic resistance is much higher in this bacterium than in E. coli. 
 
2.3.4 Effects of structural differences of antibiotics on their potentiation by efflux 
or hyperporination. 
 The strains that we created represent ideal tools to study the contribution of the 
outer membrane and active efflux on antibiotic activities in E. coli and P. aeruginosa. 
The ideal outcome of a study like this would be a set of physicochemical properties that 
define the permeation of compounds through the cell envelope. These “rules of 
permeation” could be added to Lipinski’s rule of five to significantly improve current 
drug design efforts (5, 140). Here, we are describing a preliminary screening of a library 
of structurally diverse β-lactams, cephalosporins, sulfonamides, and fluoroquinolones 
on their activity in our E. coli and P. aeruginosa strains. The data presented here are the 
results of the susceptibility testing. Tables of all results can be found in appendix B for 
E. coli and appendix C for P. aeruginosa. At the time of writing, further analysis of 
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physicochemical correlations by potentiation of the outer membrane or deletion of 
efflux is currently done in collaboration with Dr. Jerry M. Parks from the Oak Ridge 
National Laboratory and Dr. John K. Walker from the Saint Louis University School of 
Medicine. 
 Overall, we tested 18 fluoroquinolones (FQs), 23 sulfonamides (sulfas), and 44 
β-lactams (PEN), of which 28 were cephalosporins (CEF) and plotted their activities 
with respect to potentiation in pore expressing strains and efflux deficient strains of E. 
coli (Fig. 2.4) and P. aeruginosa (Fig. 2.5). The sulfonamides showed the lowest 
activity against both species, and were only marginally potentiated by inactivation of 
efflux and hyperporination. When compared to PAO1, PΔ6-Pore MICs were reduced by 
an average of only 5-fold. Most of the sulfonamides were not potentiated at all and 
other by 4-fold. The exceptions were sulfameter, sulfamethoxypyridazine, 
sulfamonomethoxine, and sulfamethoxazole, which were potentiated 16-fold in PΔ6-
Pore compared to PAO1. Of those, deletion of efflux seemed to have the biggest impact 
on activity, since most sulfonamides are small antibiotics and should be able to diffuse 
through porins of P. aeruginosa. Similarly, the activity of this class of antibiotics was 
very low in E. coli, with an average potentiation of about 2.75-fold when comparing the 
WT to ΔTolC-Pore.  
 Cephalosporins were modestly potentiated by the mutant pore and the deletion 
of efflux. With the exception of ceftriaxone and cefmenoxime, the average fold change 
was about 10 between PAO1 and PΔ6-Pore. Ceftriaxone was potentiated by 256-fold 
and cefmenoxime a staggering 1024-fold when comparing those strains. On average, 
the potentiation of cephalosporins in P. aeruginosa was similar for hyperporination and 
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deletion of efflux, both of which showed an average potentiation of about 5-fold.  
Cephalosporins had the highest average molecular weight of the four groups of about 
450 Da. In E. coli, the most potentiated cephalosporin was cefoperazone with a 256-fold 
difference between WT and ΔTolC-Pore, and the average overall potentiation was about 
10-fold for the other members of that family. Hyperporination had the biggest 
contribution to cephalosporin activity in E. coli with an average potentiation of about 5-
fold. 
 Hyperporination and the deletion of efflux had a much greater impact for the 
other β-lactams. About half of these penicillins were excellent efflux substrates in P. 
aeruginosa with MIC fold changes greater of at least 16, while the other half were not 
good substrates of efflux transporters. Some of the penicillins, like methicillin and 
nafcillin, showed a staggering 4000 to 8000-fold reduction in the MIC when comparing 
PAO1 and PΔ6-Pore. This change is mainly due to deletion of efflux, however 
hyperporination also potentiated these antibiotics by 8 and 16-fold respectively. The 
group of penicillins that was not potentiated by the deletion of efflux also only showed 
modest potentiation when strains were hyperporinated. Since most of them still had 
very high MICs, i.e. higher than 125 µM, they either have low affinity to the penicillin-
binding proteins in P. aeruginosa or the bacterium possesses other means of resistance 
to these antibiotics. The penicillins were also highly potentiated by the deletion of 
efflux in E. coli, with an average fold change of 283 between WT and ΔTolC. 
Interestingly, about half the penicillins were good substrates of TolC dependent efflux 
transporters, and the other half was only modestly or not at all potentiated by the 
deletion of efflux. However, the two groups seemed to be different in E. coli and P. 
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aeruginosa, highlighting the differences in substrate specificities of the transporters in 
the two species. 
 With the exception of nadifloxacin and moxifloxacin, fluoroquinolones were 
much more potentiated by the deletion of efflux than hyperporination in P. aeruginosa. 
The two exceptions have higher molecular weights compared to the rest of the 
fluoroquinolones, which likely results in limited diffusion across the cell envelope of P. 
aeruginosa. The average potentiation due to efflux was 35-fold, with difloxacin being 
the only fluoroquinolone with a modest 4-fold potentiation. Deletion of efflux also 
potentiated E. coli strains more than hyperporination. The average fold change due to 
deletion of efflux in E. coli was 26, with many fluoroquinolones only potentiated by 4-
fold. Hyperporination only decreased the MIC of fluoroquinolones about 5-fold in P. 
aeruginosa and about 3-fold in E. coli. Thus, these antibiotics are not limited by the 











Figure 2.4 - Antibiotic susceptibilities of members of four families in E. coli. 
A and B: Contributions of the outer membrane to susceptibilities of antibiotics from the 
four indicated groups. Pore strains are plotted on the y-axis and the parent strain on the 
x-axis. The black line indicates no fold change. C and D: similar to A and B but 










Figure 2.5 - Susceptibilities of diverse members of four families of antibiotics in P. 
aeruginosa. 
A and B: MICs of antibiotics in pore strains plotted against their respective parental 
strain, highlighting the contribution of outer membrane permeability to resistance 
against the indicated families of drugs. C and D: Similar as A and B but indicating the 







 Overall, active efflux and the outer membrane permeability affected the 
susceptibilities of both E. coli and P. aeruginosa. P. aeruginosa was overall more 
resistant to the tested antibiotics, but also showed a higher potentiation when efflux is 
deleted and the mutant pore is expressed. This highlights the differences of the cell 
envelope of the two species and the greater levels of intrinsic resistance of P. 
aeruginosa compared to E. coli. Further analysis of this data will hopefully reveal 
correlations between physicochemical properties of antibiotics and their potentiation in 
hyperporinated or efflux deficient strains. 
 
2.4 Discussion 
 Infections caused by multidrug resistant gram-negative bacteria represent a huge 
challenge for the clinician, and are expected to become more frequent in the coming 
years (1). These bacteria are especially difficult to treat due to their high intrinsic 
resistance mediated by active drug efflux and a low permeability across the outer 
membrane. This intrinsic resistance directly translates to much lower hit rates during 
drug screening, significantly diminishing the rate of drug discovery for these bacteria 
(5). New innovations in the drug development process are desperately needed in order 
to ensure that we possess a potent arsenal of antibiotics. One approach is to define 
physicochemical properties of antibiotics that could predict their propensity to cross the 
gram-negative cell envelope (140). These “rules of permeation” could be added to 
Lipinski’s rules of five to dramatically improve the development of antibiotics (5). 
 The strains described in chapter one of this dissertation provide the means to 
separate the contribution of the outer membrane and active efflux to resistance of E. coli 
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and P. aeruginosa. They represent a significantly better way to study the outer 
membrane permeability barrier then currently available methods like the use of 
polymyxins. These tools allow us to specifically screen for chemical features that allow 
better penetration of the outer membrane or circumvent efflux, and can help in the 
development of rules of permeation. Here, we described a first attempt at classifying 
antibiotics into four distinct groups based on their activity in hyperporinated or efflux 
deficient strains. Members of the proposed groups of antibiotics differ slightly between 
E. coli and P. aeruginosa, highlighting the differences in their respective outer 
membrane and arsenal of efflux transporters. Group I antibiotics are not potentiated by 
compromising the outer membrane barrier or by deleting efflux. These antibiotics likely 
follow a “self-promoted” uptake mechanism and carry positive charges. Hence, 
resistance to these antibiotics will mainly come from enzymatic inactivation or 
modification. Group II antibiotics are drugs that are affected by the outer membrane 
permeability but not by efflux. These are large antibiotics, greater than 800 Da, that are 
typically unable to penetrate through the outer membrane. Efflux transporters may not 
have evolved to utilize them as substrates due to their limited exposure to these 
compounds. The exception are some β-lactams in E. coli, which are much smaller than 
800 Da but still poor substrates of efflux transporters. Antibiotics of the group III are 
generally small, with an average molecular weight of about 350 Da, and are good efflux 
substrates. This group is potentiated by the deletion of efflux but not by 
hyperporination. Since hyperporination does not potentiate efflux proficient cells, there 
is little synergy between efflux and the outer membrane permeability for these 
antibiotics, which results in semi-efficient efflux. Group IV antibiotics are affected by 
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both hyperporination and the deletion of efflux. Thus, there is significant synergy 
between efflux transporters and the low permeability outer membrane barrier. These 
antibiotics are larger than group III antibiotics, but smaller than drugs from group II. 
Their average molecular weight is around 500 Da and they seem to be slightly less 
amphiphilic than group III antibiotics. 
 We also showed a first approach at screening of libraries of structurally diverse 
members of three antibiotic families. Although detailed analysis of physicochemical 
properties is not yet completed, we see a clear difference in the contribution of 
hyperporination and active efflux between E. coli and P. aeruginosa. This suggests that 
if there are such “rules of permeation”, they will likely differ between different gram-
negative bacteria. Differences in the properties of the outer membrane and in the arsenal 
of efflux transporters necessitates to carry out similar screenings in other gram-negative 
species like Acinetobacter and Burholderia among others. Nevertheless, our approach 
to utilize a genetically modified outer membrane porin provides valuable insight into 









Chapter 3.  Kinetic control of quorum sensing in Pseudomonas aeruginosa by 
multidrug efflux pumps. 
3.1 Abstract 
 Pseudomonas aeruginosa is an important human pathogen, the physiology 
and virulence of which are under control of quorum sensing signals. These signals 
often have dual physiological roles, functioning as toxins to other cells and as 
oxidative-stress protectors of their producer cells. Hence, their internal and 
external concentrations should be tightly controlled to maintain the steady-states. 
In this study, we analyzed the efficiencies and substrate specificities of two 
multidrug efflux transporters MexEF-OprN and MexG/HI-OpmD implicated in 
transport of quorum sensing signals in P. aeruginosa. Our results show that the 
two transporters, when overproduced, can provide clinical levels of resistance to 
diverse fluoroquinolones and protect P. aeruginosa against exogenous toxic 
phenazines. The two transporters however, differ significantly in their efficiencies, 
with MexG/HI-OpmD saturated by much lower concentrations of substrates. 
Unlike MexEF-OprN, mutational inactivation of MexG/HI-OpmD leads not only 
to a reduction of the levels of the important virulence factor pyocyanin, but also 
makes P. aeruginosa cells hypersusceptible to phenazines. In addition, we 
demonstrate that MexG binds pyocyanin, physically associates with MexHI and 
represses the activity of the transporter, pointing onto a negative regulatory role. 
We conclude that differences in kinetic properties of transporters are critical to 
maintain proper intra- and extra- cellular concentrations of phenazines and other 
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signaling molecules, and that the kinetic properties of MexG/HI-OpmD are 






















 Pseudomonas aeruginosa is a gram-negative, opportunistic human pathogen that 
is most commonly associated with nosocomial diseases and infections in cystic fibrosis 
patients (8). The increased frequency of multidrug resistant isolates of this bacterium is 
of particular concern. The World Health Organization recently published their priority 
list of antibiotic resistant bacteria and placed P. aeruginosa into the highest priority 
group (150). The pathogen achieves its high level of drug resistance mainly through the 
interplay of low outer membrane permeability and active drug efflux across the cell 
envelope (4, 5). In gram-negative bacteria, the most prominent efflux transporters 
involved in resistance are RND type transporters, largely because of their ability to 
translocate substrates across the outer membrane and their broad range of substrates (4, 
58). These transporters associate as tripartite complexes consisting of the inner 
membrane RND transporter, a membrane fusion protein (MFP), and an outer membrane 
channel (OMF). P. aeruginosa has at least twelve RND transporters encoded on its 
chromosome, which differ from each other in their level of expression and substrate 
specificity (151, 152).  
The most clinically relevant of these are MexAB-OprM (40), MexCD-OprJ (41), 
MexEF-OprN (42, 43), and MexXY (43). The role these transporters play in resistance 
is well documented and their broad substrate specificity highlights some redundancy 
between them. What is less understood is their role in cell physiology and virulence and 
why different transporters are overproduced and selected under different environmental 
conditions. It has been shown that MexAB-OprM translocates 3-oxo-acyl-homoserine 
lactones and, thus, exerts some control over the quorum sensing network of P. 
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aeruginosa (80). HHQ (4-hydroxy-2-heptylquinoline), a direct precursor for the quorum 
sensing regulator PQS (Pseudomonas Quinolone Signal), was found to be a substrate of 
MexEF-OprN (81). In fact, overexpression of this RND transporter was shown to 
decrease the production of PQS, and several PQS regulated virulence factors like 
pyocyanin and rhamnolipids (81, 153, 154). In addition, MexHI-OpmD was also shown 
to be involved in virulence of P. aeruginosa (83, 88). A mutation in either mexI or 
opmD, the RND transporter or the OMF respectively, resulted in the loss of virulence 
and a reduction of quorum sensing signaling molecules (83). These phenotypes were 
suggested to result from MexHI-OpmD transport a PQS precursor (83). Another study 
found that a deletion of MexHI-OpmD results in different colony morphology when 
compared to WT colonies, and that the transporter exports the endogenously produced 
phenazine 5-methylphenazine-1-carboxylate (5-Me-PCA) (84).  
MexHI-OpmD is a somewhat unusual RND transporter because of the fourth 
protein MexG encoded by the first gene in the operon. Sequence analysis indicates that 
MexG is an inner membrane protein with four transmembrane a-helices, a longer, and a 
shorter periplasmic loop. Other transporters containing additional genes in the operons, 
like MdtABC of E. coli (155) or TriABC from P. aeruginosa (156), contain either an 
additional RND or MFP subunit, whereas MexG does not share any homology to those 
components. It is also distinctly different from small peptides like AcrZ of E. coli, 
which changes the substrate specificity of the transporter (157). Previous studies found 
that MexG is not required for the antibiotic efflux activity of MexHI-OpmD (93), and 
that MexG binds to PQS (158). However, the function of MexG and whether or not it is 
a component of the complex is still unknown.  
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All RND transporters function in the context of the two-membrane cell envelope 
and are believed to translocate their substrates through the specific outer membrane 
channel and across the outer membrane. The outer membrane of P. aeruginosa is 
notorious for its low permeability as it lacks general porins, such as E. coli OmpF and 
OmpC. The synergistic interactions with the low permeability barrier of the outer 
membrane masks the activities of efflux pumps and complicates the assessment of their 
kinetic properties and substrate specificities (138, 159). We previously developed a 
hyperporination approach that enables influx of various compounds across the Gram-
negative outer membranes and separates contributions of active efflux and the outer 
membrane barrier in intracellular accumulation of compounds and in antibacterial 
activities (160, 161). We also found that hyperporinated P. aeruginosa strains are 
hypersusceptbile to quorum sensing signals, deficient in secretion of pyocyanin and 
prone to cell aggregation (161).  
Pyocyanin is one of the most important virulence factors in P. aeruginosa and is 
required to establish full virulence of the pathogen (162, 163). It leads to oxidative 
stress by the formation of reactive oxygen species and reduces ATP levels through the 
oxidation of NADH and NADPH in host cells (163, 164). The phenazine has significant 
antimicrobial and antifungal activity, and was also shown to be important for 
mammalian lung infections (165-167). However, P. aeruginosa is intrinsically resistant 
to its antibiotic activity. Furthermore, pyocyanin was shown to assist in the adaptation 
to anaerobic conditions by acting as an electron mediator between NADH and 
oxygen(168). The virulence factor also serves as a signaling molecule and was, in fact, 
found to upregulate expression of MexG/HI-OpmD (127). The genes required for 
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pyocyanin synthesis are located directly downstream of the mexGHI-opmD operon, 
suggesting a possible interaction between the transporter and the virulence factor. Thus, 
the intracellular and extracellular levels of this compound have to be carefully regulated 
to ensure that it can act as a signaling molecule and electron mediator without becoming 
toxic to the cell. 
Here, we analyzed substrate specificities and efflux capacities of MexG/HI-
OpmD and MexEF-OprN, the two pumps implicated in efflux of quorum sensing 
signals. We also characterized the function and the role of MexG/HI-OpmD in 
physiology of P. aeruginosa.  Our results show that MexG interacts with MexHI-OpmD 
complex and negatively affects the efflux activity of MexHI-OpmD. Unexpectedly, the 
overexpression of MexG/HI-OpmD provides strong resistance to fluoroquinolones, at 
levels comparable to those provided by MexEF-OprN. Furthermore, MexHI-OpmD is 
more efficient then MexEF-OprN in protection of P. aeruginosa against toxic 
phenazines, as seen not only in strains overexpressing the pumps but also in mutants 
lacking MexGHI-OpmD. The transporter allows for the extracellular accumulation of 
pyocyanin, while providing resistance from its toxic effects. The outer membrane 
barrier acts in synergy with RND transporters and significantly masks the efflux 
efficiencies of the transporters towards substrates. Our results suggest that, in contrast to 
MexEF-OprN, the ability of MexG/HI-OpmD to provide resistance to fluoroquinolones 
is dependent on the presence of the barrier. However, increasing the outer membrane 
permeability does not significantly affect its ability to translocate phenazines, 
highlighting its specificity towards this class of substrates. We conclude that the 
endogenous activity of MexG/HI-OpmD establishes the steady-state concentration of 
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phenazines inside and outside of cells and its ability to provide resistance to 
fluoroquinolones is strongly affected by the permeability properties of the outer 
membrane and activities of efflux pumps with overlapping substrate specificities.  
 
3.3 Results 
3.3.1 The small inner membrane protein MexG associates with MexHI-OpmD. 
 MexHI-OpmD is a unique transporter in that its operon contains a fourth gene 
encoding MexG, a protein of unknown function. To test whether MexG physically 
associates with MexHI we created a construct expressing MexG with an N-terminal 
FLAG tag, MexH, and MexI with a C-terminal His tag. The plasmid was introduced 
into PΔ3 cells lacking mexAB, mexCD, and mexXY transporters. Cells producing the 
tagged MexGHI were split into two aliquots and the short 12 Å crosslinker 
dithiobis(succinimidylpropionate) (DSP) was added to one of them, before the 
purification of MexI using His•Bind resin. After purification, the MexI-containing 
fractions were analyzed by immunoblotting with anti-His and anti-FLAG antibody to 
detect MexI and MexG, correspondingly. No MexG was detected by immunoblotting in 
MexI fractions purified from cells untreated with the cross-linker. In contrast, we could 
clearly detect MexG in elution fractions purified from the cross-linked cells, even after 
extensive washes with imidazole. Reduction of the cross-linker yielded a 15 kDa band 
reacting with anti-FLAG antibody and corresponding by size to MexG (Fig. 3.1A). We 
repeated the experiment with a plasmid expressing MexG with N-terminal FLAG tag 
and MexH with a C-terminal His tag, however we were unable to detect any 
crosslinking of MexG and MexH (Fig. 3.1A). This result suggests that there is a 
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physical interaction between MexG and MexHI-OpmD, and that MexI or the MexHI 















Figure 3.1 - MexG crosslinks to MexHI in P. aeruginosa whole cells. 
A: Immunoblotting of MexIHis (left) and MexHHis (right) elution fractions purified from 
PΔ3 cells harboring pMexGHI-FLAG and pMexGH-Flag respectively. Cells were 
treated with crosslinker prior to lysis as indicated. The lower panel shows the release of 
FLAG-tagged MexG from crosslinked samples when elution fractions are treated with a 
reducing agent (DTT), due to the presence of a disulfide bond in the crosslinker. DSP, 
Dithiobis(succinimidylpropionate); DTT, Dithiothreitol. Top panels show the 
development with anti-His and the lower panels with anti-FLAG primary antibodies. B: 
Immunoblot of membrane fractions from cells harboring the corresponding plasmids 
showing the expression of efflux transporter constructs. The respective outer membrane 
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3.3.2. MexHI-OpmD confers resistance to structurally diverse fluoroquinolones at 
comparable levels to MexEF-OprN. 
 The overexpression of MexHI-OpmD in antibiotic susceptible strains of P. 
aeruginosa was previously found to provide resistance to some antimicrobials including 
fluoroquinolones, ethidium bromide, and some dyes such as acriflavine and rhodamine 
6G (93). To compare the efficiency and substrate specificity of MexHI-OpmD to 
MexEF-OprN, which is frequently overproduced in clinical isolates and provides 
clinical levels of resistance, we created three constructs that constitutively express either 
MexGHI-OpmD, MexHI-OpmD, or MexEF-OprN using the Escherichia-Pseudomonas 
shuttle vector pBSPII (169). We confirmed similar expression levels of these constructs 
in an efflux deficient mutant PΔ4 deficient in mexAB-oprM, mexCD-oprJ, mexJKL, and 
mexXY (Figure 3.1B) and tested susceptibilities against several antibiotics (Table 1). In 
agreement with previous results, all three constructs provided resistance against the 
fluoroquinolones ciprofloxacin and levofloxacin, ethidium bromide and acriflavine but 
only the overexpression of MexEF-OprN drastically increased the MICs of 
chloramphenicol, tetracycline, triclosan, and trimethoprim. Hence, all three pumps are 
overproduced and functional. Interestingly, we were unable to find an antibiotic that is a 
substrate of MexGHI-OpmD but not MexEF-OprN. Thus, in agreement with previous 























































































































































































































































Table 3.1 - Antibiotic selectivity profiles of cells producing MexEF-OprN and 
MexG/HI-OpmD. 
CIP, ciprofloxacin; LEV, levofloxacin; EtBr, ethidium bromide; ACR, acriflavine; TET, 














































































































































































































































































































































































































Figure 3.2 - Susceptibilities of cells expressing MexHI-OpmD, MexGHI-OpmD, 
and MexEF-OprN to fluoroquinolones. 
A, D: PΔ4 (A) or PΔ4-Pore (D) cells harboring either pMexHI-OpmD, pMexGHI-
OpmD, or pMexEF-OprN are tested against a library of structurally diverse 
fluoroquinolones. MICs of fluoroquinolones are expressed as fold changes compared to 
PΔ4 cells with empty vector. Fluoroquinolones for each column from left to right: 
Ciprofloxacin, Enrofloxacin, Levofloxacin, Gatifloxacin, Moxifloxacin, Prulifloxacin, 
Sparfloxacin, Difloxacin, Lomefloxacin, Ofloxacin, Pazufloxacin, Norfloxacin, 
Pefloxacin, Sarafloxacin, and Nadifloxacin. B, C: Effect of IPTG inducer concentration 




Figure 3.3 - MIC fold differences between the transporters and due to co-
expression of MexG with MexHI-OpmD. 
A: Fold changes of the MIC between MexEF-OprN and MexHI-OpmD as calculated by 
MIC(MexEF-OprN)/MIC(MexHI-OpmD) with and without the pore. B: Fold changes 
of the MIC as a result of co-expression of MexG with MexHI-OpmD as calculated by 









Since fluoroquinolones are common substrates between these pumps, we next 
analyzed MICs of a library of 15 fluoroquinolones in PD4 cells carrying the three efflux 
pump constructs. Examples of some of these quinolones can be seen in Figure 3.4. In 
PD4, both MexEF-OprN and MexHI-OpmD transporters provided strong resistance to 
all the drugs tested, indicating that overexpression of either one of them could lead to 
clinical levels of fluoroquinolone resistance (Fig. 3.2A). Surprisingly, for the majority 
of tested fluoroquinolones there was no difference in MICs in cells producing either one 
of these two pumps. In a few cases, the MICs differed only by two-fold (Table 2 and 
Fig. 3.3A). Furthermore, for most fluoroquinolones the fold MIC change in PD4(empty 
vector)/PD4(pump) was 64-128 with a few exceptions of 32-fold change in MICs.  
Thus, despite the different substrate specificities, MexEF-OprN and MexHI-OpmD do 
not recognize differences in structures of fluoroquinolones.  
As was previously reported(93), MexG was not required for the functionality of 
MexHI-OpmD. In fact, we observed a slight reduction of the activity of MexHI-OpmD 
when MexG is co-expressed (Table 2 and Fig. 3.3). However, this difference was not 
the same across all compounds. For example, most of the compounds tested showed 2 
to 4-fold decrease in MIC, whereas the presence of MexG potentiated the activity of 
moxifloxacin by 8-fold, decreasing the MIC from 2.5 µM in PD4(pMexHI-OpmD) to an 







Figure 3.4 - Examples of structural diversity of the tested fluoroquinolones. 
Examples of structural differences between the fluoroquinolones tested. Moxifloxacin 










To determine whether the expression of MexG negatively affects the expression 
of MexHI-OpmD components, we isolated and analyzed by immunoblotting the 
membrane fractions from PD4 cells carrying the respective constructs.  Figure 3.1B 
shows the expression of the His-tagged outer membrane channels of all three plasmids. 
We did not detect significantly different levels of expression between the MexHI-
OpmD and MexGHI-OpmD constructs. This suggests that the reduction of activity for 
certain substrates when MexG is co-expressed is not due to differences in protein 
expression. Thus, the presence of MexG negatively affects the fluoroquinolone efflux 
by MexHI-OpmD to varying degrees depending on the compound. 
 
3.3.3. Hyperporination of the outer membrane differentially affects antibacterial 
activities of fluoroquinolones in cells overproducing MexEF-OprN and MexHI-
OpmD. 
We next analyzed the change in MICs of fluoroquinolones in the hyperporinated 
PD4-Pore overproducing efflux pumps, thus removing the contribution of the outer 
membrane barrier on antibacterial activities.  We first titrated IPTG, the inducer of the 
pore, to select its optimal concentration (Fig. 3.2 B and C). As expected, a decrease in 
MICs of ciprofloxacin with increasing concentration of inducer was seen in PΔ4-Pore 
strains, but not in PΔ4 strains. We measured a 4-fold decrease in the MIC of 
ciprofloxacin in PΔ4-Pore(pBSPII) in the presence of 2 mM IPTG. Similarly, we also 
observed a decrease in the MIC by 4-fold and 8-fold in the induced PΔ4-Pore(pMexEF-
OprN) or PΔ4-Pore(MexHI-OpmD), respectively. We then tested the remaining 
fluoroquinolones in PΔ4-Pore strains induced by 2 mM IPTG (Table 3 and Fig. 3.2D). 
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In agreement with previous studies (161), hyperporinated cells were much more 
susceptible to the antibiotics as seen by a decrease of the MIC up to 64-fold when 
comparing PΔ4 and PΔ4-Pore(pBSPII). Hyperporination also increased susceptibilities 
of strains overexpressing the efflux pump constructs, albeit to a different extent. 
Surprisingly, the hyperporination seemed to affect the activity of MexHI-
OpmD/MexGHI-OpmD much stronger than MexEF-OprN. For most of the 
fluoroquinolones, the overexpression of MexEF-OprN in PΔ4-Pore generated the same 
64 to 128-fold increase in MICs, efficiently overcoming the increased influx of 
antibiotics due to hyperporination. For pazufloxacin and sarafloxacin the change in 
MICs was only 16-fold, suggesting that the outer membrane barrier has a significant 
contribution in the activities of these antibiotics and MexEF-OprN is effective against 
them only when the outer membrane is intact. On the other hand, MexHI-OpmD could 
provide the same 64-fold MIC change only for nadifloxacin in hyperporinated cells, 
whereas for all other antibiotics the fold MIC changes were significantly lower with 
most in the 4 to 16-fold range. As a result, for such antibiotics as moxifloxacin, 
norfloxacin, or pefloxacin the difference in susceptibility between MexHI-OpmD and 
MexEF-OprN in hyperporinated PΔ4-Pore was up to 8-fold (Fig. 3.3A). This result 
suggests that MexEF-OprN is much more effective than MexHI-OpmD in efflux of 
fluoroquinolones and that the low permeability barrier of the outer membrane enables 
high levels of fluoroquinolone resistance provided by overexpression of MexHI-OpmD. 
In agreement, hyperporination also diminished the ability of MexGHI-OpmD to protect 
against fluoroquinolones as seen from only a 4 to 8-fold change in MICs for most of the 
compounds. Surprisingly, the efflux of nadifloxacin remained unaffected by 
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hyperporination and MexG, further supporting the conclusion that the negative effect of 
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Table 3.3 - Antibiotic resistance profile of PΔ4-Pore cells producing indicated RND 
pumps. 
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3.3.4 MexEF-OprN and MexHI-OpmD have different efficiencies in efflux of a 
fluorescent probe. 
To establish that the changes in MICs observed in hyperporinated cells are due 
to the differences in efflux activities of the overproduced pumps, we utilized a real-time 
fluorescence uptake assay. For this purpose, we used a fluorescent probe Hoechst 33342 
(HT) to carry out the uptake experiment. Like fluoroquinolones, HT is an inhibitor of 
DNA topoisomerases (170). But HT is also a fluorescent probe, the emission of which 
is significantly enhanced when it binds to lipids or DNA, allowing us to monitor its 
uptake into cells (44). The uptake data were fitted to an exponential equation to extract 
initial rates of uptake (Fig. 3.5). We observed a clear difference in the initial rates of HT 
uptake with and without the transporters present, indicating that HT is a substrate of 
both MexEF-OprN and MexHI-OpmD efflux pumps. Overexpression of MexEF-OprN 
dramatically, up to 10-fold, decreased the rates of uptake of HT both in the absence and 
presence of the pore, suggesting that HT is an excellent substrate of this efflux pump. 
Thus, in agreement with MIC measurements, hyperporination does not affect the 
activity of this pump. The overexpression of MexHI-OpmD also decreased the rates of 
HT uptake, but only in cells with an intact outer membrane. In PD4(pMexHI-OpmD) 
cells, the rate of HT uptake decreased by about 2-fold, indicating that HT is also a 
substrate of MexHI-OpmD, but it is expelled from the cells much slower than by 
MexEF-OprN. The co-expression of MexG with MexHI-OpmD further reduced its 
activity, supporting the conclusion that MexG negatively affects the activity of the 
efflux pump. Furthermore, neither MexHI-OpmD nor MexGHI-OpmD overexpression 
was able to reduce the rate of HT uptake in hyperporinated cells, indicating that unlike 
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for MexEF-OprN, the integrity of the outer membrane is critical for activity of 
MexG/HI-OpmD.  
 Taken together with MIC measurements, these results suggest that MexHI-
OpmD is a weak efflux pump that heavily relies on the outer membrane barrier for its 
activity against fluoroquinolones and HT.  Alternatively, MexHI-OpmD is presented 
with an elevated concentration of an endogenously produced substrate in 

















Figure 3.5 - Kinetic uptake measurements comparing MexEF-OprN to MexG/HI-
OpmD. 
A, C: A real-time course of intracellular accumulation of 32 µM HT in PΔ4 (A) and 
PΔ-Pore (C) expressing indicated efflux pump constructs. Kinetic curves were fitted to 
an exponential equation and initial rates were calculated. B: The plot of initial rates of 
HT accumulation in the indicated cells as a function of extracellular HT concentration. 
D: Graph of the initial rates of HT accumulation in pore expressing cells plotted against 
the extracellular HT concentration. All kinetic measurements were done in triplicate. 





3.3.5 Deletion of MexGHI-OpmD leads to a decrease in the extracellular levels of 
pyocyanin. 
We next investigated a possibility that endogenous substrates outcompete 
fluoroquinolones in the hyperporinated cells overproducing MexG/HI-OpmD.  For this 
purpose, we constructed a series strains lacking mexGHI-opmD. In addition to the wild 
type PAO1 strain, the mexGHI-opmD operon was deleted from PΔ3, PΔ4 and PΔ6 
(same as PΔ4 but with additional deletions of mexEF-oprN and triABC). For simplicity 
reasons, the ΔmexGHI-opmD variants will be referred to as PAO1ΔG, PΔ3ΔG, PΔ4ΔG, 
and PΔ6ΔG respectively. We used this approach of a stepwise deletion due to the 
known significant overlap in substrate specificities of RND transporters in P. 
aeruginosa and the progressive loss of the secretion of pyocyanin due to changes in 
quorum sensing signaling (161). 
The constructed mutants did not show an extended lag phase (Fig. 3.6A and B) 
that was previously reported (83). Similarly, we were unable to see a decrease in the 
production of PQS (data not shown), but we did notice that the ΔmexGHI-opmD 
mutants produced significantly less pyocyanin even in already pyocyanin-deficient 
efflux mutants (Fig. 3.6C). We measured the amounts of this phenazine in supernatants 
of bacterial cultures and found a noticeable, more than 2-fold, decrease in the amounts 
of pyocyanin in the cultures of all ΔmexGHI-opmD strains when compared to their 
respective parental strains (Fig. 3.6C).  
To confirm that MexGHI-OpmD is linked to the synthesis and excretion of 
pyocyanin, we measured amounts of this pigment in the cultures of the PAO1 strains 
overproducing different components of the transporter (Fig. 3.6D). When compared to 
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the wild type, PAO1 overexpressing MexGHI-OpmD or MexHI-OpmD produced twice 
the amount of pyocyanin. Expression of MexG alone did not change the amounts of 
pyocyanin in the culture medium, but expression of MexGHI without the outer 
membrane channel OpmD resulted in a 50% increase. This suggests that MexHI might 
be able to associate with another outer membrane channel to achieve at least partial 
activity. MexG does not appear to be required for this functionality of the transporter. In 
agreement with previous results, overexpression of MexEF-OprN resulted in decreased 
production of pyocyanin (153). Thus, the amount of secreted pyocyanin positively 
correlates with the expression of MexG/HI-OpmD in P. aeruginosa cells and this 









Figure 3.6 - Deletion of mexGHI-opmD results in a decrease of pyocyanin 
production. 
A and B: Growth curves of the indicated strains. C: Extracellular concentrations of 
pyocyanin in PAO1, PΔ3, PΔ4, and PΔ6 parental strains (blue) and their derivatives 
macking mexGHI-opmD (ΔG) mutants (orange). D: Extracellular concentrations of 
pyocyanin in cultures of PAO1 strains overexpressing MexEF-OprN or different 
combinations of MexG/HI-OpmD components. All measurements were done on 
cultures grown to stationary phase and in triplicate. Error bars are SD (n=3). 
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Figure 3.7 - Structures of phenazines and quorum signals. 
A: Synthesis pathway of pyocyanin, showing the intermediate 5-methyl-1-carboxylic 
Acid (5-Me-PCA). B: Pyocyanin exerts its toxic effects by reducing NADH and 
NADPH, thus reducing the intracellular levels of ATP. At the same time, this allows it 
to serve as an electron shuttle during oxygen poor conditions. C: Structures of HHQ 




3.3.6 MexGHI-OpmD provides a self-protection of P. aeruginosa to phenazines. 
Pyocyanin is a powerful toxin that inhibits the electron transport chain and 
several other pathways (162, 168). Figure 3.7B shows the oxidized and reduced forms 
of this compound. To test whether pyocyanin is a substrate of MexG/HI-OpmD we 
performed growth spot inhibition assays with PAO1 and all efflux deficient mutants 
(Fig. 3.8A). All strains that contained a chromosomal copy of mexGHI-opmD were 
fully resistant to pyocyanin. On the other hand, the efflux deficient mutants that lacked 
mexGHI-opmD were all hypersusceptible, as seen from large zones of inhibition. This is 
the first time that a P. aeruginosa strain was found to be susceptible to pyocyanin. 
PAO1ΔG was still resistant to pyocyanin at the concentrations tested, indicating that the 
constitutively expressed MexAB-OprM can provide some level of resistance to 
phenazines. However, the pyocyanin hypersusceptibility of all efflux-deficient strains 
suggests that MexG/HI-OpmD is expressed in these strains and provides immunity 
against this toxin.  
We inserted the pore into PΔ4ΔG and PΔ6ΔG strains and measured the MICs of 
pyocyanin (Table 4). Deletion of MexGHI-OpmD from PΔ4 resulted in a 4-fold 
decrease of the MIC of pyocyanin. Interestingly, this strain is 4 times more resistant to 
chloramphenicol and ciprofloxacin, which suggests that another transporter, based on 
the resistance profile likely MexEF-OprN, is overexpressed. Thus, MexEF-OprN is still 
able to provide some level of resistance to phenazines in PΔ4ΔG. The MIC of 
pyocyanin decreased by a staggering 64-fold when MexGHI-OpmD was deleted in PΔ6 
and no further decrease was observed with hyperporination, suggesting that PΔ6ΔG is 
depleted of phenazine efflux. The strain PΔ5S, same as PΔ4 but with deletion of 
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mexEF-OprN, was still completely resistant to pyocyanin, indicating that MexGHI-
OpmD is sufficient to provide efflux of this virulence factor. Furthermore, PΔ4ΔG-Pore 
showed the same MIC of pyocyanin as PΔ6ΔG, suggesting that the phenazine efflux in 
PΔ4ΔG is weak and highly dependent on the presence of the outer membrane barrier. 
On the other hand, hyperporination of PΔ4 only decreased the MIC of pyocyanin by 4-
fold, indicating that MexGHI-OpmD can compensate for the loss of the barrier and still 
provide resistance to phenazines. Taken together, these results show that MexGHI-
OpmD is highly efficient in the efflux of pyocyanin, whereas deleting MexEF-OprN has 
no effect on the MIC of phenazines. 
As could be expected based on the above results and previous studies (84), 
deletion of mexGHI-opmD resulted in a drastic increase in susceptibility to PMS, a 
close analog of 5-Me-PCA, which is an endogenous highly reactive precursor of 
pyocyanin (Fig. 3.8B). Unlike with pyocyanin, the zone of inhibition for PAO1ΔG was 
roughly 2-fold larger than for PAO1, indicating that PMS is more toxic and the 
MexG/HI-OpmD-dependent self-protection is seen even in the presence of MexAB-
OprM. Furthermore, the deletion of MexGHI-OpmD in PΔ4 resulted in a large 16-fold 
decrease of the MIC, whereas the deletion of MexEF-OprN had no impact in the MIC. 
Similar to pyocyanin, PΔ6 was still fully resistant to PMS and the deletion of MexGHI-
OpmD in that strain resulted in the same MIC as for PΔ4ΔG, further confirming that 







Figure 3.8 - MexGHI-OpmD provides resistance to pyocyanin and PMS. 
A, B: Spot assays with pyocyanin (A) and PMS (B) showing zones of inhibition in 
strains with and without mexGHI-opmD. C, D: Quantification of zones of inhibition of 









 To test whether phenazines are responsible for the decreased activity of MexHI-
OpmD against fluoroquinolones in hyperporinated strains, we set up checkerboard 
assays to analyze possible interactions between ciprofloxacin and pyocyanin with PΔ4-
Pore cells containing different plasmids (Fig. 3.9). For each strain, we calculated an 
average fractional inhibitory concentration (FIC) index. The FIC is the fraction of the 
MIC in combination with a second drug and the MIC by itself. The FIC index is the 
sum of the two FIC from each drug and is commonly used to describe interactions of 
two antimicrobials (171, 172). Generally, a FIC index of ≤0.5 represents synergy, a FIC 
index of 1 represents an additive/inconclusive effect, and an FICI of ≥2 is defined as 
antagonism between the two antimicrobials (173, 174).  We found the FIC index of ~2.3 
for the control PΔ4-Pore with empty vector, whereas the FIC indexes measured for 
PΔ4-Pore cells expressing MexEF-OprN, MexHI-OpmD, and MexGHI-OpmD were 
1.6, 1.1, and 1.0 respectively. Thus, there are no significant interactions between 
pyocyanin and ciprofloxacin in the hyperporinated strains overproducing efflux pumps 
but an antagonistic interaction is possible in the absence of these efflux pumps. The 
higher FIC indexes for MexEF-OprN and the empty vector strain could, presumably, be 
due to complementation effects of exogenous pyocyanin. These strains produce very 
low levels of pyocyanin, which also serves to maintain redox homeostasis in P. 
aeruginosa. It is likely that low, non-inhibitory concentrations of pyocyanin could 
stimulate cell growth in these strains (168). These results also show that in the strains 
overproducing MexG/HI-OpmD, ciprofloxacin and pyocyanin do not interact with each 
other and the antibacterial activities are simply additive. Thus, the reduction of the 
activity of MexHI-OpmD against fluoroquinolones in hyperporinated strains highlights 
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the low efficiency of the transporter for these substrates and that the efflux is highly 
dependent on the presence of the outer membrane barrier. This is in contrast to 
phenazine efflux of MexGHI-OpmD and shows that the outer membrane can 



















































































































































































































































































Figure 3.9 - Checkerboard assay with pyocyanin and ciprofloxacin. 
Growth of the indicated strains at different combinations of pyocyanin and 
ciprofloxacin concentrations. The optical densities of cultures are indicated with green 








3.3.7 MexG binds to pyocyanin in vitro suggesting a functional relationship with 
MexHI-OpmD. 
In all assays described above, the presence of MexG had a negative effect on the 
activity of MexHI-OpmD. We next analyzed whether MexG will bind to pyocyanin. To 
test this, we purified MexG using metal affinity chromatography and analyzed binding 
to pyocyanin by fluorescence spectroscopy. MexG contains five tryptophan residues 
that are predicted to be in the transmembrane helices. As tryptophan residues were 
excited, the emission of MexG fluorescence peaked at around 330 nm. In contrast, 
pyocyanin has a very low fluorescence at the same excitation and emission wavelengths 
(Fig. 3.10A). However, addition of increasing concentrations of pyocyanin to MexG 
significantly quenches the fluorescence of MexG and causes a slight red shift in the 
emission spectra (Fig. 3.10B), suggesting that pyocyanin binds MexG and causes a 
change in the environments of the tryptophan residues. We calculated a KD of 
pyocyanin to MexG to be about 0.6 µM (Fig. 3.11A). This suggests that the binding is 
quite strong, with the KD similar to what was previously reported for MexG and PQS 
(158). The solvent used for pyocyanin did not alter the fluorescence of MexG in the 







Figure 3.10 - Emission Spectra of MexG and Pyocyanin. 
A: Fluorescence emission spectra of MexG (1 µM) and pyocyanin (10 µM) excited at 
290 nm. B: Titration of indicated concentrations of pyocyanin into a sample of 1 µM 
MexG. Addition of pyocyanin quenches MexG fluorescence indicating a physical 
interaction. C: Effects of ethanol (solvent for pyocyanin) on fluorescence of MexG. 







Figure 3.11 - Pyocyanin binding to MexG. 
Fluorescence emission at 330 nm (excitation at 290 nm) of the wild type MexG (A) and 
MexGΔHW (B) incubated with increasing concentration of pyocyanin was measured 
and normalized as described in Methods and is plotted as a function pyocyanin 













To determine whether pyocyanin binding is specific, we constructed the MexG 
mutant MexGDHW, which contains two substitutions His95Ala and Trp98Ala at the C-
terminal end of the transmembrane domain 3.  The mutant was purified in the same 
manner as MexG WT. We repeated the fluorescence binding experiment with this 
mutant and found that the affinity of MexGDHW to pyocyanin decreased by at least 10-
fold when compared to MexG WT to a KD of about 7 µM (Fig. 3.11B). The lower 
binding affinity for MexGDHW shows that pyocyanin binds specifically to MexG, 




P. aeruginosa is a highly resistant human pathogen that is infamous for its 
colonization of lungs in cystic fibrosis patients. The high intrinsic resistance stems from 
its 12 chromosomally encoded RND efflux transporters and its outer membrane, which 
presents a significant permeability barrier for most antibiotics. Though RND 
transporters are most commonly associated with an antibiotic resistance phenotype, they 
also play important roles in the physiology of P. aeruginosa. The natural substrates of 
these transporters are often still unknown and more research is needed to elucidate the 
roles they play in establishing homeostasis of signaling molecules and virulence factors. 
In this study, we investigated the properties and functions of MexG/HI-OpmD 
efflux pump and compared them to MexEF-OprN. Our results suggest that the two 
pumps differ significantly not only in substrate specificity but also in their efflux 
efficiencies. When influx of compounds is slowed down by the low permeability barrier 
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of the outer membrane, overexpression of MexG/HI-OpmD provides resistance to a 
broad range of fluoroquinolones and endogenous phenazines at the same levels as 
MexEF-OprN. Surprisingly, despite differences in their structures, all fluoroquinolones 
appeared to be excellent substrates of both transporters, as seen from 64 to 128-fold 
changes in MICs for all tested fluoroquinolones. However, this lack of selectivity faded 
when we removed the contribution of the outer membrane to resistance by 
hyperporination, which leads to an increase of the substrate in the periplasm. This 
highlights the differences of the efficiencies of transporters toward the efflux of 
fluoroquinolones when the outer membrane permeability is compromised. As described 
above, the overproduction of MexEF-OprN increases the MICs of all FQ by 32 to 128-
fold even in hyperporinated cells (Fig. 3.2D).  However, some substrate specificity 
could be deduced from the fold MIC change in MexEF-OprN overproducers with and 
without the Pore. Norfloxacin, prulifloxacin and perfloxacin are excellent substrates of 
MexEF-OprN and their activities are only weakly (4-fold) affected by hyperporination 
(Table 3). Thus, even in the hyperporinated cells, MexEF-OprN is far from saturation 
with these fluoroquinolones. In contrast, MexEF-OprN is significantly more effective 
against nadifloxacin, sparfloxacin and difloxacin only if the influx of these drugs is very 
slow, as seen by the differences in MICs between hyperporinated and non-
hyperporinated cells (Table 2 and 3). 
The effect of hyperporination was even stronger in cells overproducing MexHI-
OpmD. The increased influx across the outer membrane significantly reduced the 
efficiency of this pump against all fluoroquinolones by 16 to 64-fold. Among the least 
affected, 16-fold change in MIC (-pore/+pore), are norfloxacin, ciprofloxacin, 
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pazufloxacin, lomofloxacin and prulifloxacin. With FQs that are strongly affected by 
hyperporination, in addition to nadifloxacin, sparfloxacin and difloxacin for which 
MexEF-OprN is not as effective, MexHI-OpmD lost its efficiency also against 
moxifloxacin, gatifloxcin and levofloxacin (64-fold MIC change). Thus, MexHI-OpmD 
is not only less efficient in efflux of FQs than MexEF-OprN, but also less specific to 
fluoroquinolones. On the other hand, MexG/HI-OpmD is more efficient in the efflux of 
phenazines, which demonstrates that these two transporters have distinctly different 
native substrates. Interestingly, for other non-FQ substrates of MexEF-OprN and 
MexHI-OpmD, hyperporination dramatically reduced the efficiency of both pumps 
(Table 1), suggesting that they are effective against these drugs only because of the low 
permeability barrier of the outer membrane. 
Previously, MexHI-OpmD was found to transport the pyocyanin precursor 5-
Me-PCA (84). Here we demonstrated that MexHI-OpmD also transports pyocyanin. 
Aendekerk et al. have shown that a disruption in mexI or opmD affects the virulence of 
PA14 cells (83), which agrees with our finding that deletion of mexGHI-OpmD leads to 
a decrease in pyocyanin production in all strains tested. Since this deletion also made 
the strains more susceptible to pyocyanin, it is likely that the decrease of its synthesis is 
due to a reduced tolerance to this toxin and that its intracellular concentration must be 
strictly controlled. This is in agreement with our finding that overexpression of MexHI-
OpmD leads to an increased level of pyocyanin synthesis in PAO1. While there is some 
functional overlap with other RND efflux pumps, our results show that MexHI-OpmD 
is likely the primary transporter for phenazines. These findings also establish a direct 
link between MexHI-OpmD and virulence in P. aeruginosa.  
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The role of MexEF-OprN in efflux of phenazines is more complex and seems to 
be similar to FQ efflux of MexGHI-OpmD. The susceptibility to pyocyanin and PMS is 
the same in PD4 and PD6 strains, suggesting that MexEF-OprN is not expressed in these 
cells and does not contribute to protection against endogenously produced phenazines. 
On the other hand, MexEF-OprN seems to be overexpressed in PΔ4ΔG but we still 
measured a 4-fold decrease in the MIC of pyocyanin between PΔ4 and PΔ4ΔG. In 
addition, hyperporination of PΔ4ΔG completely depleted the efflux capacities of the 
strain with respect to phenazines, indicating that the efflux provided by MexEF-OprN 
of these compounds is weak (Table 4). This is even more apparent for PMS, were the 
deletion of MexGHI-OpmD could not be complemented by the elevated expression of 
another efflux transporter (Table 4). Taken together, our studies show that true 
efficiencies of transporters towards certain substrates can be masked significantly by the 
presence of the outer membrane and that they can only be revealed by removing its 
contribution to resistance. It appears that the primary substrates of MexEF-OprN are 
quinolones, like its proposed quorum sensing substrate HHQ (81), whereas the primary 
substrates of MexG/HI-OpmD seem to be phenazines. 
The small membrane protein MexG appears to play a role as a negative 
regulator of the efflux activity of MexHI-OpmD. We showed here that it physically 
associates with the transporter in vivo, establishing that at least a fraction of this pump 
exists as a four-component complex MexGHI-OpmD. Antibiotic susceptibility testing 
showed a decrease in activity of the transporter in respect to some substrates when 
MexG is co-expressed (Fig. 3.3B). This decrease seems to vary depending on the 
substrate tested. Norfloxacin, ethidium bromide, and acriflavine did not show any 
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changes in activity, whereas moxifloxacin showed the biggest reduction of the MIC of 
8-fold. Some substrates might more closely resemble the native binding partner of 
MexG and can activate the small membrane protein. This could point to a regulatory 
function of MexG with respect to the activity of MexHI-OpmD. Our fluorescence 
assays showed that MexG binds pyocyanin and that this binding is specific with a KD of 
about 0.6 µM. It is possible that MexG could act as a sensor of phenazines and other 
signaling molecules in the inner membrane and modulate the activity of MexHI-OpmD 


















Figure 3.12 - Proposed model of the functional role of MexG. 
Pyocyanin has a dual role for the cell as it acts as an electron shuttle for P. aeruginosa 
during oxygen poor conditions and a virulence factor. Thus, the intracellular 
concentrations need to be regulated. When periplasmic concentrations of pyocyanin are 
low, MexG is bound to MexHI-OpmD and the transporter displays a low efflux activity. 
When the concentrations of pyocyanin increase it binds to MexG, which results in 
dissosication of the small inner membrane protein from the transporter. This increases 
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Appendix B: Drug library results E. coli 








ceftriaxone sodium trihydrate 554.58 0.10 0.02 0.10 0.00 
ceftibuten 410.425 1.56 0.39 1.56 0.39 
cefdinir 395.414 0.39 0.10 0.39 0.10 
cefepime hydrochloride 481.568 0.10 0.10 0.10 0.10 
cefmenoxime hydrochloride 511.558 2000.00 1000.00 250.00 250.00 
ceforanide 519.554 3.91 3.91 3.91 3.91 
cefotetan 575.619 0.98 0.24 0.98 0.24 
cefamandole sodium 462.503 1.56 0.39 0.39 0.10 
cefmetazole sodium 471.534 1000.00 250.00 250.00 250.00 
cefamandole nafate 490.513 3.91 3.91 3.91 0.98 
cefoperazone 645.667 0.39 0.02 0.02 0.00 
cephalexin 347.389 62.50 62.50 62.50 62.50 
cefsulodin sodium 531.539 250.00 250.00 62.50 62.50 
cefoxitin sodium 427.452 6.25 1.56 6.25 1.56 
cefuroxime sodium 424.385 15.63 0.98 0.98 0.24 
cephalosporin c zn 415.418 1000.00 1000.00 1000.00 1000.00 
cefaclor 367.807 3.91 3.91 3.91 3.91 
cephradine 349.405 2000.00 2000.00 1000.00 1000.00 
cefadroxil 363.388 62.50 62.50 62.50 62.50 
cefazolin sodium 454.507 6.25 6.25 6.25 6.25 
cefotaxime sodium 455.465 0.10 0.01 0.02 0.01 
cephalothin sodium 396.438 15.63 3.91 15.63 3.91 
cephapirin sodium 423.463 62.50 15.63 62.50 15.63 
cefonicid sodium 542.566 25.00 1.56 25.00 1.56 
cefprozil 389.426 25.00 6.25 25.00 6.25 
ceftazidime 546.576 1.56 0.39 1.56 0.39 
cefalonium 458.511 6.25 6.25 6.25 6.25 











azlocillin sodium 461.492 62.50 0.98 15.63 0.24 
meropenem 383.463 0.39 0.39 0.39 0.39 
oxacillin sodium 401.436 2000.00 62.50 0.98 0.98 
penicillin g potassium 334.39 250.00 3.91 62.50 3.91 
penicillin v potassium 350.39 1000.00 62.50 62.50 3.91 
piperacillin sodium 517.555 25.00 6.25 1.56 0.02 
cloxacillin sodium, cloxacillin 435.881 1000.00 250.00 0.98 0.98 
dicloxacillin sodium 470.326 1000.00 62.50 0.98 0.98 
hetacillin potassium 389.469 15.63 3.91 15.63 0.98 
methicillin sodium 380.415 2000.00 250.00 15.63 15.63 
moxalactam disodium 520.473 3.91 3.91 3.91 0.98 
nafcillin sodium 414.475 1000.00 62.50 3.91 0.98 
amoxicillin 365.404 62.50 15.63 62.50 15.63 
ampicillin sodium, ampicillin 349.405 2000.00 250.00 1000.00 15.63 
carbenicillin disodium, 
carbenicillin 
378.4 250.00 15.63 62.50 15.63 
ticarcillin disodium 384.427 2000 2000 1000 1000 
 





ciprofloxacin 331.342 0.39 0.1 0.1 0.02 
enrofloxacin 359.395 1 0.25 0.25 0.02 
levofloxacin 361.368 1 0.25 0.25 0.02 
gatifloxacin 375.394 1 0.25 0.25 0.02 
moxifloxacin hydrochloride 429.484 6.25 0.39 0.39 0.02 
prulifloxacin 443.425 0.25 0.06 0.02 0 
sparfloxacin 392.4 1 0.25 0.25 0.02 
difloxacin hydrochloride 399.391 1.56 0.39 0.39 0.1 
lomefloxacin 351.348 1.56 1.56 0.39 0.1 
ofloxacin 361.368 1.56 0.39 0.39 0.1 
pazufloxacin mesylate 318.3 1 0.25 0.25 0.02 
oxolinic acid 261.23 100 25 6.25 1.56 
flumequine 261.248 1 1 0.25 0.06 
norfloxacin 319.331 1 0.25 0.06 0.02 
pefloxacine mesylate 333.357 0.39 0.39 0.1 0.02 
sarafloxacin hydrochloride 385.364 6.25 0.39 0.1 0.02 
nadifloxacin 360.38 1.56 0.39 0.39 0.1 
192 
orbifloxacin 395.38 0.39 0.1 0.1 0.02 
 





sulfameter 280.303 1000 1000 1000 1000 
sulfamethoxypyridazine 280.303 1000 1000 2000 1000 
phthalylsulfathiazole 403.432 1000 1000 1000 1000 
sulfachlorpyridazine 284.722 1000 1000 1000 1000 
sulfaphenazole 314.362 2000 1000 1000 1000 
sulfadimethoxine 310.329 2000 2000 2000 2000 
sulfaquinoxaline sodium 300.336 2000 1000 250 1000 
sulfaguanidine 214.245 2000 1000 2000 2000 
sulfamonomethoxine 280.303 1000 250 250 250 
sulfamethazine 278.33 2000 2000 2000 2000 
sulfamethizole 270.331 2000 2000 250 250 
sulfamethoxazole 253.278 1000 250 1000 1000 
sulfapyridine 249.289 2000 2000 2000 1000 
sulfathiazole 255.317 2000 2000 250 250 
sulfisoxazole 267.304 2000 2000 250 250 
sulfanilamide 172.205 2000 2000 2000 2000 
sulfabenzamide 276.311 1000 1000 1000 1000 
sulfacetamide 214.242 2000 2000 2000 2000 
sulfadiazine 250.277 1000 2000 2000 2000 
sulfamerazine 264.304 1000 1000 1000 1000 
sulfisoxazole acetyl 309.341 2000 2000 250 250 
sulfacarbamide 215.23 2000 2000 250 250 
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trihydrate 554.58 15.6 0.97 3.9 0.015 3.9 0.061 
ceftibuten 410.425 4000 2000 1000 1000 1000 62.5 
cefdinir 395.414 1000 1000 1000 1000 1000 62.5 
cefepime hydrochloride 481.568 3.9 0.24 0.24 0.061 0.24 0.061 
cefmenoxime 
hydrochloride 511.558 15.6 0.97 0.97 0.0152 0.24 0.0152 
ceforanide 519.554 2000 2000 2000 2000 2000 250 
cefotetan 575.619 1000 62.5 1000 62.5 250 62.5 
cefamandole sodium 462.503 2000 2000 2000 1000 1000 250 
cefmetazole sodium 471.534 2000 2000 1000 250 1000 250 
cefamandole nafate 490.513 2000 2000 2000 1000 1000 250 
cefoperazone 645.667 3.9 0.24 0.97 0.97 0.97 0.97 
cephalexin 347.389 4000 4000 4000 4000 4000 250 
cefsulodin sodium 531.539 3.9 0.97 0.97 0.24 0.97 0.24 
cefoxitin sodium 427.452 2000 1000 2000 250 1000 62.5 
cefuroxime sodium 424.385 1000 250 1000 250 1000 250 
cephalosporin c zn 415.418 1000 1000 1000 1000 1000 1000 
cefaclor 367.807 2000 2000 2000 250 1000 62.5 
cephradine 349.405 2000 2000 2000 2000 2000 2000 
cefadroxil 363.388 2000 2000 2000 2000 2000 2000 
cefazolin sodium 454.507 2000 2000 2000 2000 2000 2000 
cefotaxime sodium 455.465 62.5 3.9 3.9 3.9 3.9 3.9 
cephalothin sodium 396.438 2000 2000 2000 2000 2000 1000 
cephapirin sodium 423.463 2000 2000 2000 2000 2000 1000 
cefprozil 389.426 1000 1000 1000 1000 1000 250 
ceftazidime 546.576 3.9 0.24 3.9 0.24 3.9 0.24 
cefalonium 458.511 1000 1000 1000 1000 1000 250 













azlocillin sodium 461.492 62.5 3.9 3.9 0.24 3.9 0.061 
ofloxacin 361.368 1.56 0.39 0.39 0.097 0.097 0.024 
meropenem 383.463 6.25 1.56 0.39 0.097 0.39 0.097 
oxacillin sodium 401.436 2000 250 250 3.90625 62.5 0.97 
penicillin g 
potassium 334.39 2000 2000 2000 250 1000 250 
penicillin v 
potassium 350.39 2000 2000 2000 250 2000 250 
piperacillin sodium 517.555 15.625 0.97 0.97 0.97 3.9 0.061 
cloxacillin sodium, 
cloxacillin 435.881 8000 1000 1000 62.5 1000 3.9 
dicloxacillin 
sodium 470.326 2000 1000 62.5 3.9 62.5 3.9 
hetacillin 
potassium 389.469 2000 250 1000 15.6 1000 15.6 
methicillin sodium 380.415 2000 250 15.6 3.9 15.6 0.24 
moxalactam 
disodium 520.473 62.5 15.625 62.5 0.97 62.5 0.97 
nafcillin sodium 414.475 1000 62.5 62.5 0.24 3.9 0.24 
amoxicillin 365.404 1000 1000 1000 62.5 1000 15.6 
ampicillin sodium, 




378.4 1000 250 15.6 0.97 15.6 0.24 

















ciprofloxacin 331.342 0.39 0.1 0.1 0.02 0.02 0.006 
enrofloxacin 359.395 1 0.25 0.25 0.02 0.06 0.004 
levofloxacin 361.368 1 0.25 0.25 0.02 0.02 0.004 
gatifloxacin 375.394 1 0.25 0.25 0.02 0.06 0.004 
moxifloxacin 
hydrochloride 429.484 6.25 0.39 0.39 0.02 0.1 0.024 
prulifloxacin 443.425 0.25 0.06 0.02 0 0.02 0.004 
sparfloxacin 392.4 1 0.25 0.25 0.02 0.02 0.004 
difloxacin 
hydrochloride 399.391 1.56 0.39 0.39 0.1 0.39 0.097 
lomefloxacin 351.348 1.56 1.56 0.39 0.1 0.1 0.024 
ofloxacin 361.368 1.56 0.39 0.39 0.1 0.1 0.024 
pazufloxacin 
mesylate 318.3 1 0.25 0.25 0.02 0.02 0.016 
flumequine 261.248 100 25 6.25 1.56 1.56 0.097 
norfloxacin 319.331 1 1 0.25 0.06 0.06 0.016 
pefloxacine 
mesylate 333.357 1 0.25 0.06 0.02 0.02 0.004 
sarafloxacin 
hydrochloride 385.364 0.39 0.39 0.1 0.02 0.02 0.006 
nadifloxacin 612.6375 6.25 0.39 0.1 0.02 0.1 0.002 











sulfameter 280.303 1000 1000 250 250 250 62.5 
sulfamethoxypyridazine 280.303 1000 1000 250 250 250 62.5 
phthalylsulfathiazole 403.432 1000 1000 1000 1000 1000 1000 
sulfachlorpyridazine 284.722 1000 1000 250 250 250 250 
sulfaphenazole 314.362 1000 1000 1000 250 1000 250 
sulfadimethoxine 310.329 1000 1000 1000 250 1000 250 
sulfaquinoxaline sodium 300.336 1000 1000 1000 4000 1000 250 
sulfaguanidine 214.245 4000 4000 4000 4000 4000 4000 
sulfamonomethoxine 280.303 1000 1000 250 250 250 62.5 
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sulfamethazine 278.33 1000 1000 250 250 250 250 
sulfamethizole 270.331 250 250 250 250 250 250 
sulfamethoxazole 253.278 1000 250 250 62.5 250 62.5 
sulfapyridine 249.289 1000 1000 250 250 250 250 
sulfathiazole 255.317 250 250 62.5 62.5 250 62.5 
sulfisoxazole 267.304 250 250 250 62.5 250 62.5 
sulfanilamide 172.205 4000 4000 4000 4000 4000 4000 
sulfabenzamide 276.311 1000 1000 1000 1000 1000 1000 
sulfacetamide 214.242 4000 4000 1000 1000 4000 1000 




















Appendix D: LN(OD600) vs time plots of growth curves 
 
LN(OD) vs time plots of growth measurements. The steepest part of the curve was used 
to calculate growth rates using linear regression. Six time points were used to determine 
the rates and were selected based on the highest coefficient of determination (r2). 
E. coli: 
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P. aeruginosa: 
 
